WO2013157528A1 - 2環性化合物 - Google Patents
2環性化合物 Download PDFInfo
- Publication number
- WO2013157528A1 WO2013157528A1 PCT/JP2013/061231 JP2013061231W WO2013157528A1 WO 2013157528 A1 WO2013157528 A1 WO 2013157528A1 JP 2013061231 W JP2013061231 W JP 2013061231W WO 2013157528 A1 WO2013157528 A1 WO 2013157528A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- phenyl
- substituent
- ethyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
- C07D311/54—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 substituted in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
Definitions
- the present invention relates to a bicyclic compound having a heme-independent activation action on soluble guanylate cyclase and a pharmaceutical containing the same.
- Soluble guanylate cyclase is an enzyme that produces cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP), and is composed of a dimer of an ⁇ subunit and a ⁇ subunit.
- the ⁇ subunit is bound to heme, and the iron coordinated with heme usually interacts with the histidine residue at the 105th amino acid to form an inactivated structure.
- Nitric oxide (NO) is known to be the main sGC activator in the body, interacts with heme iron present in the ⁇ subunit of sGC, and interacts with heme iron and the histidine residue of the ⁇ subunit.
- CGMP produced by activated sGC then activates protein kinases and ion channels, and plays various roles such as relaxation of vascular smooth muscle, inhibition of platelet activation, inhibition of cell proliferation, and olfactory neurotransmission. Plays.
- Non-patent Documents 1 and 2 Heart failure, endothelial dysfunction, atherosclerosis, peripheral vascular disease, angina pectoris, thrombosis, myocardial infarction, erectile dysfunction, renal dysfunction and the like.
- nitrate agents such as nitroglycerin are widely used to activate sGC. These donate exogenous NO to cause the activation of sGC and develop a pharmacological action.
- nitric acid is known to have a resistance phenomenon in addition to side effects, which is a serious drawback of this drug. It has been suggested that the resistance phenomenon of nitrates is due to a mechanism different from sGC, such as a decrease in the activity of mitochondrial aldehyde dehydrogenase involved in the release of NO (Non-patent Document 3). The resulting compound can avoid the resistance phenomenon.
- Non-Patent Document 4 As sGC activators other than NO, direct sGC activators dependent on heme represented by Riociguat (Patent Document 1) are known. Although these compounds activate sGC without depending on NO, it has been shown that sGC activation ability cannot be sufficiently exhibited under the oxidation conditions of heme iron (Non-patent Document 5).
- compounds with direct sGC activation that do not depend on the oxidation state of heme are hypertension, pulmonary hypertension, heart failure, endothelial dysfunction, atherosclerosis, peripheral vascular disease, It is considered effective for the treatment or prevention of various diseases such as heart disease, thrombosis, myocardial infarction, erectile dysfunction, and renal dysfunction.
- Patent Document 2 discloses Cinaciguat and derivatives thereof
- Patent Document 3 discloses pyrazoles and triazole derivatives
- Patent Document 4 discloses 2,6.
- -Disubstituted pyridine derivatives are disclosed in Patent Document 5 as heterocyclic derivatives.
- An object of the present invention is to provide a novel compound that has a heme-independent activation action on soluble guanylate cyclase and is useful as a pharmaceutical product.
- the present inventors have synthesized various compounds and screened using soluble guanylate cyclase activating action as an index.
- a compound having a structure in which a bicyclic compound is bonded to a nitrogen atom is highly heme-independent, It has been found that it has an excellent activating action for soluble guanylate cyclase and is useful as a preventive or therapeutic agent for various diseases involving soluble guanylate cyclase, and has completed the present invention.
- the present invention has the general formula (1)
- A represents a C 1 -C 3 linear alkylene group, wherein one methylene group may be substituted with O or S;
- n represents an integer of 3 to 5;
- X 1 and X 2 each independently represent CH or N;
- W 1 and W 2 each independently represent a carboxyl group or a tetrazolyl group;
- V represents a C 1 -C 8 linear or branched alkylene group, wherein one methylene group may be substituted with O or S;
- R is the following formula
- R 1 , R 2 , R 3 , R 4 and R 5 are a hydrogen atom, a halogen atom, an optionally substituted C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, C 3 -C 6 cycloalkyl group, C 3 -C 6 cycloalkoxy group, halo C 1 -C 4 alkyl group, halo C 1 -C 4 alkoxy group, vinyl group which may have a substituent, substituent An ethynyl group which may have a substituent on the aromatic ring, an aryloxy group which may have a substituent on the aromatic ring, a benzyl group which may have a substituent on the benzene ring, benzene A phenethyl group that may have a substituent on the ring, a benzyloxy group that may have a substituent on the benzene ring, a benzylsulfonyl group
- this invention provides the pharmaceutical containing the compound represented by the said General formula (1), its pharmaceutically acceptable salt, or those solvates.
- the present invention also provides a pharmaceutical composition comprising a compound represented by the above general formula (1), a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier. Is.
- the present invention also provides a compound represented by the above general formula (1) for preventing or treating diseases involving soluble guanylate cyclase such as heart failure, hypertension, pulmonary hypertension, ischemic heart disease, Provided are pharmaceutically acceptable salts or solvates thereof.
- the present invention is represented by the above general formula (1) for producing a prophylactic or therapeutic drug for diseases involving soluble guanylate cyclase, such as heart failure, hypertension, pulmonary hypertension, and ischemic heart disease.
- the use of the compounds, pharmaceutically acceptable salts or solvates thereof is provided.
- the present invention also provides an administration of an effective amount of the compound represented by the above general formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof, heart failure, hypertension, lung
- the present invention provides a method for preventing or treating diseases involving soluble guanylate cyclase such as hypertension and ischemic heart disease.
- the compound of the present invention is highly heme-independent, has an excellent activating effect on soluble guanylate cyclase, and is useful as a prophylactic or therapeutic agent for various diseases involving soluble guanylate cyclase.
- diseases that can be prevented or treated by activating the soluble guanylate cyclase include heart failure, hypertension, pulmonary hypertension, and ischemic heart disease.
- the “linear alkylene group” refers to a linear alkylene group having a predetermined number of carbon atoms. Specific examples include a methylene group, — (CH 2 ) 2 —, — (CH 2 ) 3 —, — (CH 2 ) 4 —, — (CH 2 ) 5 —, — (CH 2 ) 6 — and the like. .
- the “branched alkylene group” refers to a branched alkylene group having a predetermined number of carbon atoms.
- one methylene group may be substituted with O or S” of “linear or branched alkylene group” means any methylene of the linear or branched alkylene group. Indicates that the group is substituted with O or S.
- the “linear alkylene group” is a methylene group having 1 carbon atom, —O— and —S— are also included.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- C 1 -C 6 alkyl group refers to a linear alkyl group having 1 to 6 carbon atoms or a branched alkyl group having 3 to 6 carbon atoms.
- Examples of C 1 -C 6 alkyl groups include methyl, ethyl, n-propyl, n-butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n -Hexyl group and the like.
- C 1 -C 6 alkoxy group refers to a group in which one hydrogen atom of the above “C 1 -C 6 alkyl group” is substituted with an oxygen atom.
- the C 1 -C 6 alkoxy group includes a methoxy group, an ethoxy group, and n-propoxy group.
- the “C 3 -C 6 cycloalkyl group” refers to a cyclic alkyl group having 3 to 6 carbon atoms. Specific examples include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.
- C 3 -C 6 cycloalkoxy group refers to a group in which one hydrogen atom of the “C 3 -C 6 cycloalkyl group” is substituted with an oxygen atom.
- Specific examples include a cyclopropoxy group, a cyclobutoxy group, a cyclopentyloxy group, and a cyclohexyloxy group.
- halo C 1 -C 4 alkyl group the C 1 -C 4 alkyl group is a linear or branched alkyl group having a carbon number of 3 or 4 having 1 to 4 carbon atoms A group in which one or more hydrogen atoms are substituted with halogen atoms.
- halo C 1 -C 4 alkyl groups include chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, dibromomethyl, tribromomethyl, 2 -Chloroethyl group, 2,2-dichloroethyl group, 2,2,2-trichloroethyl group, 2-fluoroethyl group, 2,2-difluoroethyl group, 2,2,2-trifluoroethyl group, 1,1 , 2,2-tetrafluoroethyl group, pentafluoroethyl group, 2-bromoethyl group, 2,2,2-tribromoethyl group, 3,3,3-trichloropropyl group, 3,3,3-trifluoropropyl Group, 3,3,3-tribromopropyl group, 4,4,4-trichlorobutyl group, 4,4,4-trifluorobutyl group
- halo C 1 -C 4 alkoxy group refers to a group in which one hydrogen atom of the “halo C 1 -C 4 alkyl group” is substituted with an oxygen atom.
- halo C 1 -C 4 alkoxy groups include chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-chloroethoxy, 2,2-dichloroethoxy 2,2,2-trichloroethoxy group, 2-fluoroethoxy group, 2,2-difluoroethoxy group, 2,2,2-trifluoroethoxy group, 1,1,2,2-tetrafluoroethoxy group, penta Examples include fluoroethoxy group, 3,3,3-trichloropropoxy group, 3,3,3-trifluoropropoxy group, 4,4,4-trichlorobutoxy group, 4,4,4-trifluorobutoxy group.
- the “aryl group” refers to a monocyclic or polycyclic aromatic hydrocarbon group having 6 to 10 carbon atoms.
- the aryl group include a phenyl group and a naphthyl group, and more specifically include a phenyl group, a 1-naphthyl group, and a 2-naphthyl group.
- the “aryloxy group” refers to a group in which one hydrogen atom of the “aryl group” is substituted with an oxygen atom.
- the aryloxy group include a phenoxy group and a naphthoxy group, and more specifically include a phenoxy group, a 1-naphthoxy group, and a 2-naphthoxy group.
- substituent means one or more, preferably 1 to 2, more preferably 1 or more of the same or different substituents at an unsubstituted or substitutable position. It shows having.
- substituents include a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, a C 3 -C 6 cycloalkyl group, a C 3 -C 6 cycloalkoxy group, and a halo C 1 -C 4 alkyl group.
- group, aryl group and the like. The definition of each substituent is as defined above, and may further have a substituent.
- the halogen atom represented by R 1 , R 2 , R 3 , R 4 and R 5 is preferably a fluorine atom or a chlorine atom, more preferably a chlorine atom.
- the substituent is C 1 -C 6. Examples thereof include an alkoxy group, a C 3 -C 6 cycloalkyl group, and a C 3 -C 6 cycloalkoxy group. Among them, a C 3 -C 6 cycloalkyl group is preferable, and a cyclohexyl group is particularly preferable.
- the C 1 -C 6 alkyl group which may have a substituent is preferably a methyl group, an ethyl group, an isopropyl group, a tert-butyl group, a 2-methoxyethyl group, a 2-cyclopropylethyl group, or a 2-cyclohexylethyl group. And more preferably an isopropyl group, a tert-butyl group or a 2-cyclohexylethyl group.
- the C 1 -C 6 alkoxy group represented by R 1 , R 2 , R 3 , R 4 and R 5 is preferably a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group or a tert-butoxy group. More preferred are tert-butoxy groups.
- the C 3 -C 6 cycloalkyl group represented by R 1 , R 2 , R 3 , R 4 and R 5 is preferably a cyclopropyl group or a cyclohexyl group, more preferably a cyclopropyl group.
- Examples of the C 3 -C 6 cycloalkoxy group represented by R 1 , R 2 , R 3 , R 4 and R 5 include a cyclopropyloxy group, a cyclopentyloxy group, and a cyclohexyloxy group, and a cyclohexyloxy group is more preferable.
- the halo C 1 -C 4 alkyl group represented by R 1 , R 2 , R 3 , R 4 and R 5 is preferably a C 1 -C 4 alkyl group substituted with one or more fluorine atoms, more preferably Is a C 1 -C 4 alkyl group substituted with 1 to 5 fluorine atoms.
- halo C 1 -C 4 alkoxy group represented by R 1 , R 2 , R 3 , R 4 and R 5 is preferably a C 1 -C 4 alkoxy group substituted with one or more fluorine atoms, more preferably Is a C 1 -C 4 alkoxy group substituted with 1 to 5 fluorine atoms.
- trifluoromethoxy group 2,2,2-trifluoroethoxy group, 1,1,2,2-tetrafluoroethoxy group, pentafluoroethoxy group, and the like, more preferably trifluoromethoxy group. is there.
- the substituent is A C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group or an aryl group is preferred, and the aryl group is preferably a phenyl group, and the aryl group is further a halogen atom, a C 1 -C 6 alkyl group or a halo C 1 It may have a substituent such as —C 4 alkyl group.
- the vinyl group is preferably unsubstituted or has 1 to 2 substituents, and particularly preferably has 1 substituent.
- the ethynyl group is preferably unsubstituted or has one substituent.
- a vinyl group, a cyclohexyl vinyl group, a styryl group, an ethynyl group, a 3-methyl-1-butyn-1-yl group examples thereof include a cyclopropylethynyl group, a cyclohexylethynyl group, a phenylethynyl group, and the like, and a cyclohexylvinyl group, a styryl group, and a cyclohexylethynyl group are preferable.
- the aromatic ring of the aryl group optionally having a substituent on the aromatic ring represented by R 1 , R 2 , R 3 , R 4 and R 5 or the aryloxy group optionally having a substituent on the aromatic ring Is a benzene ring.
- the aromatic ring has a substituent
- the substituent is preferably a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, or a halo C 1 -C 4 alkyl group.
- the aryl group or aryloxy group which may have a substituent is preferably unsubstituted or has 1 to 2 substituents, and preferably has 1 substituent in the para position.
- Benzyl group which may have a substituent on the benzene ring represented by R 1 , R 2 , R 3 , R 4 and R 5 Phenethyl group which may have a substituent on the benzene ring, Substituent on the benzene ring A benzyloxy group which may have a substituent on the benzene ring, a benzylamino group which may have a substituent on the benzene ring, or a substituent on the benzene ring
- a good phenyloxymethyl group, a phenylsulfanylmethyl group that may have a substituent on the benzene ring, or a phenylaminomethyl group that may have a substituent on the benzene ring (hereinafter referred to as benzyl group to phenylaminomethyl group) Benzyl group etc.) are preferably unsubstituted or have 1 to 2 substituents on the
- the substituent is preferably a halogen atom, a C 1 -C 6 alkyl group, or a halo C 1 -C 4 alkyl group, more preferably a halo C 1 -C 4 alkyl group, and most preferably a trifluoromethyl group.
- a phenethyl group, a benzyloxy group, and a benzylsulfanyl group are preferable, and a phenethyl group is particularly preferable.
- C 1 -C 3 linear alkylene group represented by A include a methylene group, —O—, —S—, —CH 2 CH 2 —, —CH 2 O—, —CH 2 S—, —OCH 2 —, —SCH 2 —, — (CH 2 ) 3 —, —OCH 2 CH 2 —, —SCH 2 CH 2 —, —CH 2 OCH 2 —, —CH 2 SCH 2 —, —CH 2 CH 2 O—, —CH 2 CH 2 S—.
- a methylene group —O—, —CH 2 CH 2 —, —CH 2 O—, —OCH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 OCH 2 —, —CH 2 SCH 2 —, — CH 2 CH 2 O— is preferable, and —CH 2 CH 2 — and —CH 2 O— are particularly preferable.
- n is most preferably 4.
- X 2 is most preferably CH.
- W 1 and W 2 are preferably carboxyl groups.
- C 1 -C 8 linear or branched alkylene group represented by V include a methylene group, —O—, —S—, —CH 2 CH 2 —, —CH (CH 3 ) O—. , —CH 2 CH (CH 3 ) —, —CH 2 CH (CH 3 ) O—, —CH 2 CH (CH 3 ) S—, —CH 2 O—, —CH 2 S—, —OCH 2 —, -SCH 2 -is mentioned.
- -CH 2 CH 2 -, - CH (CH 3) O -, - CH 2 O- are preferable, -CH 2 O-is particularly preferred.
- m is an integer of 1 or 2
- Y 1 and Y 2 are each independently a methylene group, O or S, but not simultaneously S
- a group represented by the following formula may be mentioned.
- the group represented by R includes the following formula
- R 1 may have a C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group, a C 1 -C 6 alkoxy group, a halo C 1 -C 4 alkyl group, or a substituent which may have a substituent.
- R 1 has a C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group, an optionally substituted vinyl group, an optionally substituted ethynyl group, and a benzene ring having a substituent.
- the substitution position of R 1 is preferably a meta position or a para position.
- the substituent on the C 1 -C 6 alkyl group is preferably a C 1 -C 6 alkoxy group, a C 3 -C 6 cycloalkyl group, or a C 3 -C 6 cycloalkoxy group.
- the substituent on the vinyl group or ethynyl group include C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group, phenyl group, halogenophenyl group, C 1 -C 6 alkylphenyl group, halo C 1 -C A 4- alkylphenyl group is preferred.
- aryl group a phenyl group is preferable, and as the aryloxy group, a phenoxy group is preferable.
- substituent on the aryl or aryloxy a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group is preferable.
- a halo C 1 -C 4 alkyl group is preferred.
- the substituent on the benzene ring is preferably a halogen atom, a C 1 -C 6 alkyl group, or a halo C 1 -C 4 alkyl group.
- R 2 includes a vinyl group which may have a substituent, an ethynyl group which may have a substituent, a benzyl group which may have a substituent on the benzene ring, and a substituent on the benzene ring.
- Good More preferred is a benzylsulfanyl group.
- Most preferred is a phenethyl group which may have a substituent on the benzene ring.
- examples of the substituent on the vinyl group or ethynyl group include C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group, phenyl group, halogenophenyl group, C 1 -C 6 alkylphenyl group, A halo C 1 -C 4 alkylphenyl group is preferred.
- the substituent on the benzene ring is preferably a halogen atom, a C 1 -C 6 alkyl group, or a halo C 1 -C 4 alkyl group.
- R 3 is preferably a hydrogen atom, an optionally substituted C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, or a halo C 1 -C 4 alkyl group. Most preferably, it is a hydrogen atom.
- the substitution position of R 3 is most preferably the para position.
- the substituent on the C 1 -C 6 alkyl group is preferably a C 1 -C 6 alkoxy group, a C 3 -C 6 cycloalkyl group, or a C 3 -C 6 cycloalkoxy group.
- R 4 may be a hydrogen atom, an optionally substituted C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group, a halo C 1 -C 4 alkyl group, or an aromatic ring having a substituent.
- a good aryl group or an aryloxy group which may have a substituent on the aromatic ring is preferred. Most preferably, it is a hydrogen atom.
- the substitution position of R 4 is preferably the 6-position.
- the substituent on the C 1 -C 6 alkyl group is preferably a C 1 -C 6 alkoxy group, a C 3 -C 6 cycloalkyl group, or a C 3 -C 6 cycloalkoxy group.
- aryl group a phenyl group is preferable, and as the aryloxy group, a phenoxy group is preferable.
- substituent on the aryl or aryloxy a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxy group is preferable.
- a halo C 1 -C 4 alkyl group is preferred.
- R 5 is a hydrogen atom, a benzyl group that may have a substituent on the benzene ring, a phenethyl group that may have a substituent on the benzene ring, a benzyloxy group that may have a substituent on the benzene ring, Benzylsulfanyl group which may have a substituent on the benzene ring, benzylamino group which may have a substituent on the benzene ring, phenyloxymethyl group which may have a substituent on the benzene ring, substitution on the benzene ring
- a phenylsulfanylmethyl group which may have a group or a phenylaminomethyl group which may have a substituent on the benzene ring is preferable, and a hydrogen atom and a phenethyl group are more preferable.
- the substitution position of R 5 is preferably the 6-position.
- the substituent on the benzene ring is preferably a halogen atom, a C 1 -C 6 alkyl group, or a halo C 1 -C 4 alkyl group.
- A is a methylene group, —O—, —CH 2 CH 2 —, —CH 2 O—, —OCH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 OCH 2 —, —CH 2 SCH 2 — or —CH 2 CH 2 O—;
- n is an integer from 3 to 5;
- W 1 and W 2 are carboxyl groups;
- V is —CH 2 CH 2 —, —CH (CH 3 ) O— or —CH 2 O—;
- R is
- R 1 , R 2 , Y 1 , Y 2 and m are the same as described above.
- A is a methylene group, —O—, —CH 2 CH 2 —, —CH 2 O—, —OCH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 OCH 2 —, —CH 2 SCH 2 — or —CH 2 CH 2 O—;
- n is an integer of 4;
- W 1 and W 2 are carboxyl groups;
- V is —CH 2 CH 2 —, —CH (CH 3 ) O— or —CH 2 O—;
- R is
- R 1 , R 2 , Y 1 , Y 2 and m are the same as described above.
- R 1 may have a C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group, a C 1 -C 6 alkoxy group, a halo C 1 -C 4 alkyl group which may have a substituent.
- it has a C 1 -C 6 alkyl group, a C 3 -C 6 cycloalkyl group, an optionally substituted vinyl group, an optionally substituted ethynyl group, and a benzene ring having a substituent.
- the substituents on the alkyl group, vinyl group, ethynyl group, aryl group, aryloxy group and benzene ring are preferably the same as described above.
- R 2 includes a vinyl group which may have a substituent, an ethynyl group which may have a substituent, a benzyl group which may have a substituent on the benzene ring, and a substituent on the benzene ring.
- a phenethyl group which may have a substituent on the benzene ring.
- the substituents on the vinyl group, ethynyl group and benzene ring are preferably the same as described above.
- R is
- Examples of the compound represented by the general formula (1) according to the present invention include the following compounds.
- 1- ⁇ N- (4-carboxybutyl) -N- [2- [2- [4- (2-phenylethyl) benzyloxy] phenyl] ethyl] amino ⁇ indane-5-carboxylic acid (Example 1) 5- ⁇ N- (4-carboxybutyl) -N- [2- [2- [4- (2-phenylethyl) benzyloxy] phenyl] ethyl] amino ⁇ -5,6,7,8-tetrahydronaphthalene- 2-carboxylic acid (Example 2) 5- ⁇ N- (4-carboxybutyl) -N- [2- [2- [4- (2-phenylethyl) benzyloxy] phenyl] ethyl] amino ⁇ -6,7,8,9-tetrahydro-5H -Benzocycloheptene-2-carbox
- the compound of the general formula (1) may give rise to isomers such as geometric isomers, optical isomers, stereoisomers, tautomers, etc. of the general formula (1) of the present invention.
- the compound includes any one of the isomers or a mixture thereof.
- the compound (1) of the general formula of the present invention includes compounds labeled with isotopes (eg, 2 H, 3 H, 14 C, 35 S, 125 I, etc.) and the like.
- the present invention also includes a pharmaceutically acceptable salt of the compound of the general formula (1).
- inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, formate, acetate, trichloroacetate, trifluoroacetate, propion Acid salt, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, tartrate, citrate, methanesulfonate, ethanesulfonate, benzenesulfonic acid Salt, p-toluenesulfonate (4-methylbenzenesulfonate), acid addition salt with organic acid such as aspartate or glutamate; sodium salt, potassium salt, magnesium salt, calcium salt, ammonium salt, aluminum Examples thereof include base addition salts with inorganic bases such as salts, and organic bases such as methylamine, ethylamine, ethanolamine, lysine and ornithine
- the present invention may include hydrates, various solvates and crystal polymorphs of the compound (1) of the present invention and pharmaceutically acceptable salts thereof, but is not limited to any of them. These may be a single crystal form or a mixture of crystal forms, both of which are included.
- the compound (1) of the present invention may be converted into a prodrug by a pharmacologically acceptable group.
- pharmacologically acceptable group for forming a prodrug include, for example, Prog. Med. 5, 2157-2161 (1985) and “Development of pharmaceuticals” (Yodogawa Shoten, 1990), Volume 7, Molecular Design 163-198.
- the compound of the general formula (1) of the present invention is based on the basic skeleton or the kind of the substituent. Utilizing the characteristics, it can be produced by applying various synthetic methods known per se relating to substituent introduction and functional group conversion.
- the compound of the general formula (1) can be produced, for example, according to the following formula.
- U 1 and U 2 correspond to W 1 and W 2 , respectively, and W 1 and / Alternatively, when W 2 is a tetrazolyl group, U 1 and / or U 2 is a cyano group, and when W 1 and / or W 2 is a carboxyl group, U 1 and / or U 2 represents CO 2 R 6 .
- Q 1 and Q 2 correspond to W 1 and W 2 respectively, and when W 1 and / or W 2 is a tetrazolyl group, Q 1 and / or Q 2 is also a tetrazolyl group, and W 1 and / or W 2 is When it is a carboxyl group, Q 1 and / or Q 2 represents CO 2 R 6 , where R 6 represents a C 1 -C 6 alkyl group, and E represents a leaving group or a hydroxyl group.
- the “leaving group” refers to a group that can be replaced in the presence of a base or a group having an activated oxygen atom.
- halogen atom trihalogenomethyloxy group such as trichloromethyloxy group
- lower alkanesulfonyloxy group such as methanesulfonyloxy group and ethanesulfonyloxy group
- trifluoromethanesulfonyloxy group pentafluoroethanesulfonyloxy group and the like
- halogeno lower alkanesulfonyloxy groups such as benzenesulfonyloxy group, p-toluenesulfonyloxy group, and p-nitrobenzenesulfonyloxy group.
- Step 1 Nosyl protection.
- Compound (3) can be produced by reacting compound (2) with a nitrobenzenesulfonyl group-introducing agent in the presence or absence of a base, in the absence of a solvent, or in an inert solvent.
- the nitrobenzenesulfonyl group introducing agent used is, for example, 2-nitrobenzenesulfonyl chloride or 4-nitrobenzenesulfonyl chloride.
- the amount of the nitrobenzenesulfonyl group-introducing agent to be used is generally 1 to 5 equivalents, preferably 1 to 2 equivalents, relative to compound (2).
- the base used is, for example, an alkali metal carbonate, an alkali metal hydrogen carbonate, an alkali metal hydroxide or a tertiary organic amine such as triethylamine or diisopropylethylamine.
- the solvent used include aromatic hydrocarbons such as benzene and toluene, nitriles such as acetonitrile, propionitrile, and butyronitrile, halogenated hydrocarbons such as chloroform and dichloromethane, diethyl ether, and tetrahydrofuran (hereinafter referred to as THF). ) And the like, water, or a mixture thereof.
- the reaction temperature is usually ⁇ 30 ° C. to 40 ° C., preferably 0 ° C. to room temperature.
- the reaction time is usually 0.5 to 24 hours, preferably 0.5 to 3 hours.
- a compound (2) is marketed or can be manufactured by a well-known method.
- Step 2 Mitsunobu reaction.
- Compound (5) can be produced by reacting compound (3) and compound (4) in the presence of a dehydration condensing agent, in the absence of a solvent, or in an inert solvent.
- the amount of compound (4) to be used is generally 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound (3).
- the dehydrating condensing agent used include azodicarboxylic acid compounds such as diethyl azodicarboxylate and 1,1′-azobis (N, N-dimethylformamide) and phosphines such as triphenylphosphine and tri-n-butylphosphine. The combination of is mentioned.
- the amount of the dehydrating condensing agent to be used is generally 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound (3).
- the solvent used include aromatic hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as chloroform and dichloromethane, ethers such as diethyl ether and THF, N, N-dimethylformamide (hereinafter referred to as DMF). And amides such as dimethylacetamide.
- the reaction temperature is usually ⁇ 30 ° C. to 40 ° C., preferably 0 ° C. to room temperature.
- the reaction time is usually 1 to 48 hours, preferably 1 to 24 hours.
- Compound (4) is commercially available or can be produced by a known method.
- Step 3 Nosyl deprotection reaction.
- Compound (6) can be produced by reacting compound (5) in the presence of a base and a deprotecting reagent, in the absence of a solvent, or in an inert solvent.
- the deprotecting reagent used is, for example, primary or secondary organic amines such as n-propylamine and pyrrolidine; thiols such as 1-dodecanethiol, thiophenol and thioglycolic acid.
- the amount of the deprotecting reagent to be used is generally 1-5 equivalents, preferably 1-2 equivalents, relative to compound (5).
- Examples of the base used include alkali metal carbonates, alkali metal hydrogen carbonates, alkali metal hydrides, alkali metal alkoxides, and tertiary organic amines.
- Examples of the solvent used include nitriles such as acetonitrile, propionitrile and butyronitrile, halogenated hydrocarbons such as chloroform and dichloromethane, amides such as DMF and dimethylacetamide, and mixtures thereof.
- the reaction temperature is usually ⁇ 30 ° C. to 40 ° C., preferably 0 ° C. to room temperature.
- the reaction time is usually 1 to 48 hours, preferably 1 to 24 hours.
- Step 4 Alkylation.
- Compound (8) can be produced by reacting compound (6) and compound (7) with a base, if necessary, in the presence of an additive, in the absence of a solvent, or in an inert solvent.
- the amount of compound (7) to be used is generally 1-5 equivalents, preferably 1-3 equivalents, relative to compound (6).
- the base used include organic amines such as alkali metal carbonates, alkali metal hydrogen carbonates, alkali metal hydrides, alkali metal alkoxides, triethylamine, diisopropylethylamine, and pyridine.
- phase transfer catalysts such as alkali metal iodides, tetrabutylammonium salts, and crown ethers.
- Solvents used include aromatic hydrocarbons such as benzene and toluene, nitriles such as acetonitrile, propionitrile, and butyronitrile, halogenated hydrocarbons such as chloroform and dichloromethane, ketones, diethyl ether, THF, and the like.
- Ethers alcohols such as methanol, ethanol and 2-propanol, amides such as DMF and dimethylacetamide, or a mixture thereof.
- the reaction temperature is usually room temperature to 150 ° C., preferably room temperature to 100 ° C.
- the reaction time is usually 5 to 72 hours, preferably 8 to 48 hours.
- Step 5 Tetrazole cyclization.
- Compound (9) is a known method for converting a cyano group to a tetrazolyl group when at least one of U 1 and U 2 is a cyano group in compound (8), for example, in the presence of an azide in an inert solvent. It can manufacture by the method made to react with.
- the azides used are, for example, metal azide salts, trialkyltin azides, ammonium azides, trimethylsilyl azides.
- additives can be appropriately used as necessary. Additives used are, for example, aluminum chloride, quaternary ammonium salts, magnesium salts, dialkyltin oxides, zinc chloride.
- the solvent used include aromatic hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as chloroform and dichloromethane, ethers such as diethyl ether and THF, amides such as DMF and dimethylacetamide, and the like. It is a mixture.
- the reaction temperature is usually room temperature to 180 ° C, preferably 50 ° C to 120 ° C.
- the reaction time is usually 5 to 72 hours, preferably 8 to 48 hours.
- the compound of general formula (1) can be produced by subjecting compound (9) to a deesterification reaction when at least one of Q 1 and Q 2 is CO 2 R 6 in compound (9).
- the deesterification reaction can be generally performed according to a well-known method in the field of organic synthetic chemistry, depending on the type of ester group (CO 2 R 6 ).
- the compound of the general formula (1) can be produced by performing a hydrolysis reaction in the presence of a base.
- the base used is, for example, an alkali metal carbonate, an alkali metal hydroxide, an alkaline earth metal hydroxide or an alkali metal alkoxide.
- Solvents used are ethers such as diethyl ether and THF, alcohols such as methanol, ethanol and 2-propanol, water or a mixture thereof. In this hydrolysis reaction, water is essential.
- the reaction temperature is usually 0 ° C. to 150 ° C., preferably room temperature to 80 ° C.
- the reaction time is usually 1 to 48 hours, preferably 3 to 24 hours.
- an optically active compound of the general formula (1) can be produced by subjecting optically active compounds (8) and (9) to a deesterification reaction. Furthermore, in the compound of the general formula (1), an optically active compound of the general formula (1) can also be produced through HPLC fractionation using a chiral column.
- Step 7 Deprotection.
- Compound (12) can be produced by subjecting compound (11) to a deprotection reaction.
- the deprotection reaction can be generally performed according to a method well known in the field of synthetic organic chemistry (for example, TW Greene, PG Wuts, Greene's Protective Groups in Organic Synthesis. Fourth Edition, 2006). , John Wiley & Sons, Inc.).
- Step 8 Alkylation reaction, Mitsunobu reaction.
- compound (13) when E is a leaving group, compound (8) can be produced from compound (12) and compound (13) in the same manner as in Step 4 above.
- the compound (13) when E is a hydroxyl group, the compound (8) can be produced from the compound (12) and the compound (13) in the same manner as in the above step 2.
- the compound of the general formula (I) may be produced by obtaining the compound (6) by the method of the following formula.
- Step 9 Oxidation reaction.
- Compound (15) can be produced by reacting compound (14) with an oxidizing agent in an inert solvent.
- the oxidizing agent used include 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3 (1H) -one (DMP), 1-hydroxy-1,2
- a high valent iodine reagent such as benziodoxol-3 (1H) -one-1-oxide (IBX); a combination of an aluminum alkoxide and a hydrogen acceptor such as benzoquinone, benzophenone, acetone, benzaldehyde;
- a combination of Nate (TPAP) or 2,2,6,6-tetramethyl-1-piperidinyloxy radical (TEMPO) and a co-oxidant such as hypochlorite, bromite, N-chlorosuccinimide; Dimethyl sulfoxide (hereinafter referred to as DMSO) and dicyclohe
- the amount of the oxidizing agent to be used is generally 1-10 equivalents, preferably 1-3 equivalents, relative to compound (14).
- a base such as pyridine or sodium hydrogencarbonate can be added as necessary.
- Solvents used include aromatic hydrocarbons such as benzene and toluene, nitriles such as acetonitrile, propionitrile, and butyronitrile, halogenated hydrocarbons such as chloroform and dichloromethane, and ethers such as diethyl ether and THF.
- Esters such as ethyl acetate, propyl acetate and butyl acetate, amides such as DMF and dimethylacetamide, sulfoxides such as DMSO and sulfolane, or a mixture thereof.
- the reaction temperature is usually ⁇ 30 ° C. to 100 ° C., preferably 0 ° C. to room temperature.
- the reaction time is usually 0.5 to 24 hours, preferably 1 to 8 hours.
- Step 10 Reductive amination.
- Compound (6) is obtained by reacting compound (15) and compound (16) in the absence or presence of an acid, in the absence of a solvent or in an inert solvent, first to obtain a Schiff base, which is then It can be produced by reacting in the presence of a reducing agent.
- the amount of compound (16) to be used is generally 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound (15).
- the acid used include inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid, and organic acids such as formic acid, acetic acid, propionic acid, methanesulfonic acid and p-toluenesulfonic acid.
- Examples of the reducing agent used include boron hydride compounds such as borane-tetrahydrofuran complex, sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride; aluminum hydride compounds such as lithium aluminum hydride; hydrogen Is mentioned.
- the amount of the reducing agent to be used is generally 1-10 equivalents, preferably 1-5 equivalents, relative to compound (15).
- Solvents used include aromatic hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as chloroform and dichloromethane, ethers such as diethyl ether and THF, and esters such as ethyl acetate, propyl acetate and butyl acetate.
- Alcohols such as methanol, ethanol, 2-propanol or mixtures thereof.
- the reaction temperature is usually ⁇ 78 ° C. to 150 ° C., preferably 0 ° C. to 60 ° C.
- the reaction time is usually 5 minutes to 24 hours, preferably 30 minutes to 4 hours.
- Compound (16) is commercially available or can be produced by a known method.
- the compound of the present invention thus obtained has a sGC activating action that is excellent in heme independence, as shown in Test Examples described later. Therefore, the compound of the present invention is useful as a medicament for the prevention and treatment of diseases involving sGC in animals including humans, particularly various diseases in which sGC activation action is effective. Examples of the disease include heart failure, hypertension, pulmonary hypertension, or ischemic heart disease.
- the compound of the present invention When the compound of the present invention is used as a medicine, it can be administered orally or parenterally.
- the dose of the compound of the present invention is appropriately determined depending on the individual case in consideration of the target disease or symptom, the age, weight, sex, etc. of the administration subject.
- the dose of the compound of the present invention per day for an adult is 1 to 1000 mg, preferably 3 to 300 mg, more preferably 10 to 200 mg.
- the daily dose for adults When administered intravenously, the daily dose for adults is usually 0.01-100 mg / kg body weight, preferably 0.01-50 mg, more preferably 0.01-20 mg. Dosage in several to multiple doses.
- the pharmaceutical composition of the present invention can be produced by an ordinary method using one or more compounds of the present invention and a pharmaceutically acceptable additive.
- Examples of the pharmaceutical composition of the present invention for oral administration include tablets, pills, capsules, granules, powders, emulsions, solutions, suspensions, syrups, and elixirs. These can be usually produced as a pharmaceutical composition in which one or more compounds of the present invention are mixed with additives such as pharmaceutically acceptable diluents, excipients and carriers. Also, binders, disintegrants, lubricants, swelling agents, swelling aids, coating agents, plasticizers, stabilizers, preservatives, antioxidants, coloring agents, solubilizers, suspending agents, emulsifiers, sweetness Additives such as an agent, preservative, buffering agent, wetting agent and the like may be included.
- Examples of the pharmaceutical composition of the present invention for parenteral administration include injections, suppositories, eye drops, inhalants, ointments, gels, creams, patches and the like. These can be usually produced as a pharmaceutical composition in which one or more compounds of the present invention are mixed with additives such as pharmaceutically acceptable diluents, excipients and carriers.
- Stabilizers such as an agent, a thickener, a wetting agent, a filler, an absorption enhancer, a suspending agent, and a binder may be included.
- the pharmaceutical composition containing the compound of the present invention may appropriately contain other kinds of medicinal components such as diuretics as long as the object of the present invention is not violated.
- THF tetrahydrofuran
- Reference Example 4 3- (3-Methoxycarbonylphenylsulfanyl) propionic acid Reference Example 3 (10.3 g) was dissolved in acetone (150 mL), and potassium carbonate (17.0 g), 3-bromopropionic acid ( 10.3 g) was added and stirred at room temperature for 2.5 hours. The solvent was distilled off under reduced pressure, and the residue was suspended in water. The pH was adjusted to 1 with 6 mol / L hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
- Reference Example 8 5-Oxo-5,6,7,8-tetrahydroquinoline-2-carboxylic acid To Reference Example 7 (6.05 g), concentrated hydrochloric acid (70 mL) was added, and the mixture was stirred with heating under reflux for 14 hours. After cooling to room temperature, concentrated hydrochloric acid was distilled off under reduced pressure. The residue was dissolved in a 25% methanol / chloroform solution, washed with saturated brine, and dried over anhydrous sodium sulfate. After evaporating the solvent under reduced pressure, the residue was suspended in diisopropyl ether and collected by filtration to give the title compound (6.38 g) as a pale yellow powder.
- Table 1 shows the compounds of Reference Examples 16 to 18 produced by the same method as Reference Example 15 using the compounds of Reference Examples 5, 9, and 14.
- Table 2 shows the compounds of Reference Examples 23 to 24 produced by the same method as in Reference Example 22 using the corresponding raw materials.
- Reference Example 26 4- (2-Cyclohexylethyl) benzyl alcohol Reference Example 25 (283 mg) was dissolved in methanol (7.0 mL), palladium-fibroin (57.0 mg) was added, and the mixture was brought to atmospheric pressure and room temperature under a hydrogen atmosphere. And stirred for 45 minutes. After filtration through celite, it was washed with methanol, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (5-35% ethyl acetate / hexane) to give the title compound (206 mg) as a yellow powder.
- Reference Example 35 6-thiochromanmethyl alcohol Reference Example 34 (340 mg) was dissolved in methanol (10 mL), and sodium borohydride (91.2 mg) was added in several portions under ice-cooling. Stir for hours. Under ice-cooling, a saturated aqueous ammonium chloride solution was added and stirred, and the solvent was distilled off under reduced pressure. After dilution with ethyl acetate, the mixture was washed successively with water and saturated brine. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (6-50% ethyl acetate / hexane) to give the title compound as a colorless oil.
- Reference Example 37 1-hydroxy-6-phenylethynyl-1,2,3,4-tetrahydronaphthalene The title compound (485 mg) was obtained as a white powder from Reference Example 36 (493 mg) in the same manner as in Reference Example 11.
- Table 3 shows compounds of Reference Examples 40 to 46 produced by the same method as in Reference Example 39 using the corresponding raw materials.
- Reference Example 49 2- ⁇ 2- [2- [4- (2-Phenylethyl) phenyl] ethyl] phenyl ⁇ acetaldehyde Reference Example 48 (496 mg) was dissolved in DMSO (10 mL), IBX (840 mg) was added, and For 1.5 hours. Ethyl acetate and water were sequentially added, and the mixture was stirred at room temperature for 1 hour. The precipitate was filtered and washed with ethyl acetate. After the separation operation, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the extract was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure.
- the residue was purified by silica gel column chromatography (20% ethyl acetate / hexane) to give the title compound as a yellow oil.
- Tables 4 and 5 show Reference Example compounds 54 to 61 produced by the same method as Reference Example 53 using the corresponding compound (4) and the compound of Reference Example 51 or 52.
- Table 6 shows the compounds of Reference Examples 63 to 70 produced by the same method as Reference Example 62 using the compounds of Reference Examples 54 to 61.
- Reference examples 66, 67, 68, and 70 were isolated as hydrochlorides.
- Tables 7 and 8 show the compounds of Reference Examples 72 to 81 produced by the same method as Reference Example 71 using the compounds of Reference Example 50 and Reference Examples 63 to 70.
- Table 9 shows compounds of Reference Examples 83 and 84 produced by the same method as Reference Example 82 using the compounds of Reference Examples 72 and 74.
- Reference Example 85 1- ⁇ N- (4-methoxycarbonylbutyl) -N- [2- [2- [4- (2-phenylethyl) benzyloxy] phenyl] ethyl] amino ⁇ indan-5-carboxylate
- Reference Example 82 (298 mg) was dissolved in acetonitrile (2.8 mL), 4- (2-phenylethyl) benzyl chloride (194 mg) and potassium carbonate (145 mg) were added, and the mixture was stirred with heating under reflux for 18 hr. After cooling to room temperature, the solvent was distilled off under reduced pressure, and the residue was suspended in water and extracted with ethyl acetate.
- Tables 10 to 13 show the compounds of Reference Examples 86 to 108 produced by the same method as Reference Example 85 using the corresponding compound (13) and the compound of Reference Example 83 or 84.
- Table 14 shows compounds of Reference Examples 110 to 115 produced by the same method as in Reference Example 109 using the corresponding compound (13) and the compound of Reference Example 83.
- Reference Example 119 3-Cyano-8-oxo-5,6,7,8-tetrahydroisoquinoline Reference Example 118 (1.53 g) was dissolved in DMF (12 mL), and zinc cyanide (487 mg), tetrakis was dissolved in an argon atmosphere. (Triphenylphosphine) palladium (0) (299 mg) was added, and the mixture was stirred at 80 ° C. for 3 hr. After filtration through celite, the mixture was diluted with ethyl acetate and washed with saturated brine.
- Reference Example 120 8-oxo-5,6,7,8-tetrahydroisoquinoline-3-carboxylic acid
- the title compound (685 mg) was obtained as a white powder from Reference Example 119 (672 mg) in the same manner as in Reference Example 8.
- 1 H-NMR (CDCl 3 ) ⁇ : 9.14 (1H, s), 8.15 (1H, s), 3.10 (2H, t, J 6.0 Hz), 2.81-2.73 (2H, m), 2.29-2.19 (2H, m).
- Reference Example 122 8-hydroxy-5,6,7,8-tetrahydroisoquinoline-3-carboxylate methyl
- the title compound (448 mg) was quantitatively obtained from Reference Example 121 (432 mg) in the same manner as in Reference Example 11. .
- Table 15 shows Reference Example Compounds 123 and 124 produced by the same method as in Reference Example 53 using the corresponding Compound (4) and the compound of Reference Example 51.
- Table 16 shows the compounds of Reference Examples 125 and 126 produced by the same method as in Reference Example 62 using the compounds of Reference Examples 123 and 124.
- Table 17 shows the compounds of Reference Examples 127 and 128 produced by the same method as in Reference Example 71 using the compounds of Reference Examples 125 and 126.
- Table 18 shows the compounds of Reference Examples 129 and 130 produced by the same method as in Reference Example 82 using the compounds of Reference Examples 127 and 128.
- Tables 19 to 20 show the compounds of Reference Examples 131 to 139 prepared by the same method as in Reference Example 85 using the corresponding compound (13) and the compounds of Reference Example 82, Reference Example 83, Reference Example 129 or 130. Show.
- Table 21 shows the compounds of Reference Examples 140 and 141 prepared by the same method as in Reference Example 109 using the corresponding compound (13) and the compound of Reference Example 83. *
- Example 1 1- ⁇ N- (4-Carboxybutyl) -N- [2- [2- [4- (2-phenylethyl) benzyloxy] phenyl] ethyl] amino ⁇ indane-5-carboxylic acid Reference Example 85 (391 mg) was dissolved in THF (1.0 mL) and methanol (2.1 mL), 2.5 mol / L aqueous sodium hydroxide solution (1.0 mL) was added, and the mixture was stirred at 50 ° C. for 1.5 hr. After cooling to room temperature, the solvent was distilled off under reduced pressure, and the residue was redissolved in water.
- Tables 22 to 32 show the compounds of Examples 2 to 49 produced by the same method as in Example 1 using the corresponding compounds of Reference Examples.
- Tables 33 to 37 show the compounds of Examples 50 to 69 produced by the same method as in Example 1 using the corresponding optically active compounds of Reference Examples.
- the cells were suspended in a culture solution, seeded in a 96-well plate, and cultured at 37 ° C. for 24 hours.
- Assay buffer 1 140 mmol / L sodium chloride, 5 mmol / L potassium chloride, 0.5 mmol / L magnesium chloride, 0.01 mmol / L calcium chloride, 10 mmol / L glucose, 0.4 mmol / L magnesium sulfate, 10 mmol / L 4-
- Fura2-AM a fluorescent Ca 2+ indicator
- the indicator solution dissolved in 1 was added and incubated at 37 ° C. for 60 minutes. After removing the culture solution and washing with assay buffer 1, a test compound solution was added and incubated at room temperature for 10 minutes. A plate was placed in a fluorescence measuring apparatus (FlexStation II, Molecular Devices), and the intracellular calcium concentration was measured as a fluorescence intensity ratio obtained from each excitation wavelength at excitation wavelengths of 340 nm and 380 nm and a detection wavelength of 510 nm.
- test compound solution was prepared by dissolving each test compound in DMSO so as to be 10 mmol / L, and then assay buffer 2 (140 mmol / L sodium chloride, 5 mmol / L potassium chloride, 0.5 mmol / L magnesium chloride, 1 mmol / L calcium chloride, 10 mmol / L glucose, 0.4 mmol / L magnesium sulfate, 10 mmol / L 4- (2-hydroxyethyl) piperazin-1-ylethanesulfonic acid, 125 ⁇ mol / L Diluted with sulfinpyrazone, 100 ⁇ mol / L isobutylmethylxanthine, 10 ⁇ mol / L 1H- [1,2,4] -oxadiazole [4,3-a] quinoxalin-1-one (hereinafter ODQ), pH 7.4) And prepared.
- assay buffer 2 140 mmol / L sodium chloride, 5 mmol / L potassium chloride, 0.5
- test results are shown in Table 38 and Table 39.
- sGC activation can be measured as a change in intracellular Ca 2+ concentration.
- ODQ is an oxidant specific to the heme-binding iron atom. In the presence of ODQ, the heme iron atom is oxidized, so that heme-dependent activation of sGC does not occur. Therefore, the maximum sGC activation action including heme-dependent activation can be evaluated in the absence of ODQ, and the heme-independent sGC activation action can be evaluated in the presence of ODQ.
- the sGC activity shows a maximum value and becomes constant at a concentration of 10 ⁇ mol / L or more in any test compound including Synasiguat as a comparative example, and at 10 ⁇ mol / L.
- the activity value was defined as the sGC activity maximizing ability (Emax) of each test compound.
- Emax sGC activity maximizing ability
- Test Example 2 Heme Independence of sGC Activation Action Further representative compounds were 0.0001, 0.001, 0.003, 0.01, and 0.03 by the same method as Test Example 1, respectively. , 0.1, 1, 10 ⁇ mol / L activity was measured.
- the degree of heme-independent action in the sGC activation action of each test compound is determined by dividing the EC 50 in the absence of ODQ by the EC 50 in the presence of ODQ for the EC 50 determined from the concentration-activity curve prepared as described above. Determined by In other words, it can be said that the smaller the EC 50 ratio, the smaller the change in the sGC activation effect due to the presence or absence of ODQ, and the more heme independent.
- EC 50 values were determined by measuring the activity of test compounds at concentrations of 0.0001, 0.001, 0.003, 0.01, 0.03, 0.1, 1, 10 ⁇ mol / L, respectively. Calculated by a four-parameter logistic model. The test results are shown in Table 40.
- the abdominal aorta is composed of ice-cooled Krebs-Henseleit solution (KH solution) (118 mmol / L sodium chloride, 4.7 mmol / L potassium chloride, 1.2 mmol / L magnesium sulfate, 1.2 mmol / L potassium dihydrogen phosphate, 25 mmol /
- KH solution Krebs-Henseleit solution
- the connective tissue attached around the blood vessels was removed in L sodium bicarbonate, 2.5 mmol / L calcium chloride, 10 mmol / L glucose, pH 7.4). Thereafter, a ring specimen having a length of 2 mm was prepared and fixed in a 5 mL organ bath filled with KH solution.
- the KH liquid was maintained at 37 ° C., and 95% O 2 and 5% CO 2 mixed gas was aerated.
- the specimen was stabilized for 1 hour at a static tension of 1 g. During this time, the KH solution was changed twice.
- the tension of the specimen was recorded on a multichannel recorder through a pickup and an amplifier. After sample stabilization, contraction was induced with 1 ⁇ mol / L phenylephrine (Phe) and cumulative administration of each compound (0.001, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 , 30, 100, 1000, 10000 nmol / L).
- the bicyclic compound of the present invention since the bicyclic compound of the present invention, its pharmaceutically acceptable salt, or a solvate thereof has an excellent sGC activation action independent of heme, various diseases on which soluble guanylate cyclase acts For example, it is useful as a therapeutic or prophylactic agent for heart failure, hypertension, pulmonary hypertension, or ischemic heart disease.
Abstract
Description
nは3から5の整数を示し;
X1及びX2は互いに独立してCH又はNを示し;
W1及びW2は互いに独立してカルボキシル基又はテトラゾリル基を示し;
VはC1-C8直鎖状又は分岐鎖状アルキレン基を示し、ここでメチレン基1個がO又はSで置換されていてもよく;
Rは下式
ここで、R1、R2、R3、R4及びR5は水素原子、ハロゲン原子、置換基を有しても良いC1-C6アルキル基、C1-C6アルコキシ基、C3-C6シクロアルキル基、C3-C6シクロアルコキシ基、ハロC1-C4アルキル基、ハロC1-C4アルコキシ基、置換基を有しても良いビニル基、置換基を有しても良いエチニル基、芳香環に置換基を有しても良いアリール基、芳香環に置換基を有しても良いアリールオキシ基、ベンゼン環に置換基を有しても良いベンジル基、ベンゼン環に置換基を有しても良いフェネチル基、ベンゼン環に置換基を有しても良いベンジルオキシ基、ベンゼン環に置換基を有しても良いベンジルスルファニル基、ベンゼン環に置換基を有しても良いベンジルアミノ基、ベンゼン環に置換基を有しても良いフェニルオキシメチル基、ベンゼン環に置換基を有しても良いフェニルスルファニルメチル基、又はベンゼン環に置換基を有しても良いフェニルアミノメチル基を示し、
mは1又は2の整数を示し、
Y1及びY2は互いに独立してメチレン、O又はSを示し、ただし同時にSでない。)
で表される化合物、その薬学的に許容される塩又はそれらの溶媒和物を提供するものである。
また、本発明は、上記一般式(1)で表される化合物、その薬学的に許容される塩又はそれらの溶媒和物、及び薬学的に許容される担体を含有する医薬組成物を提供するものである。
また、本発明は、心不全、高血圧症、肺高血圧症、虚血性心疾患等の可溶性グアニル酸シクラーゼが関与する疾患を予防又は治療するための、上記一般式(1)で表される化合物、その薬学的に許容される塩又はそれらの溶媒和物を提供するものである。
また、本発明は、心不全、高血圧症、肺高血圧症、虚血性心疾患等の可溶性グアニル酸シクラーゼが関与する疾患を予防又は治療薬を製造するための、上記一般式(1)で表される化合物、その薬学的に許容される塩又はそれらの溶媒和物の使用を提供するものである。
また、本発明は、上記一般式(1)で表される化合物、その薬学的に許容される塩又はそれらの溶媒和物の有効量を投与することを特徴とする、心不全、高血圧症、肺高血圧症、虚血性心疾患等の可溶性グアニル酸シクラーゼが関与する疾患の予防又は治療方法を提供するものである。
本明細書中「分岐鎖状アルキレン基」とは、所定の数の炭素原子を有する分岐鎖状のアルキレン基を示す。具体的には、-CH(CH3)-、-CH(C2H5)-、-CH(C3H7)-、-CH(C4H9)-、-CH(C5H11)-、-CH2CH(CH3)-、-CH2CH2CH(CH3)-などが挙げられる。
本明細書中、「C1-C6アルコキシ基」は、上記「C1-C6アルキル基」の1個の水素原子が酸素原子に置換した基を示す。具体的には炭素数1~6の直鎖状アルコキシ基又は炭素数3~6の分岐鎖アルコキシ基であり、C1-C6アルコキシ基の例としては、メトキシ基、エトキシ基、n-プロポキシ基、イソプロポキシ基、n-ブトキシ基、イソブトキシ基、tert-ブトキシ基、n-ペンチルオキシ基、n-ヘキシルオキシ基等が挙げられる。
本明細書中、「C3-C6シクロアルキル基」とは、炭素数3~6の環状のアルキル基を示す。具体的にはシクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基が挙げられる。
本明細書中、「ハロC1-C4アルコキシ基」とは、上記「ハロC1-C4アルキル基」の1個の水素原子が酸素原子に置換した基を示す。ハロC1-C4アルコキシ基の例として、クロロメトキシ基、ジクロロメトキシ基、トリクロロメトキシ基、フルオロメトキシ基、ジフルオロメトキシ基、トリフルオロメトキシ基、2-クロロエトキシ基、2,2-ジクロロエトキシ基、2,2,2-トリクロロエトキシ基、2-フルオロエトキシ基、2,2-ジフルオロエトキシ基、2,2,2-トリフルオロエトキシ基、1,1,2,2-テトラフルオロエトキシ基、ペンタフルオロエトキシ基、3,3,3-トリクロロプロポキシ基、3,3,3-トリフルオロプロポキシ基、4,4,4-トリクロロブトキシ基、4,4,4-トリフルオロブトキシ基等が挙げられる。
本明細書中、「アリールオキシ基」とは、上記「アリール基」の1個の水素原子が酸素原子に置換した基を示す。アリールオキシ基の例としては、フェノキシ基、ナフトキシ基が挙げられ、より具体的には、フェノキシ基、1-ナフトキシ基、2-ナフトキシ基が挙げられる。
R1、R2、R3、R4及びR5で示される置換基を有していてもよいC1-C6アルキル基が置換基を有する場合、当該置換基としてはC1-C6アルコキシ基、C3-C6シクロアルキル基、C3-C6シクロアルコキシ基が挙げられ、中でもC3-C6シクロアルキル基が好ましく、シクロヘキシル基が特に好ましい。置換基を有しても良いC1-C6アルキル基として好ましくはメチル基、エチル基、イソプロピル基、tert-ブチル基、2-メトキシエチル基、2-シクロプロピルエチル基、2-シクロヘキシルエチル基であり、イソプロピル基、tert-ブチル基、2-シクロヘキシルエチル基がより好ましい。
R1、R2、R3、R4及びR5で示されるC1-C6アルコキシ基としては、メトキシ基、エトキシ基、n-プロポキシ基、イソプロポキシ基、tert-ブトキシ基が好ましく、メトキシ基及びtert-ブトキシ基がより好ましい。
R1、R2、R3、R4及びR5で示されるC3-C6シクロアルキル基としては、シクロプロピル基、シクロヘキシル基が好ましく、シクロプロピル基がより好ましい。
R1、R2、R3、R4及びR5で示されるC3-C6シクロアルコキシ基としては、シクロプロピルオキシ基、シクロペンチルオキシ基、シクロヘキシルオキシ基が挙げられ、シクロヘキシルオキシ基がより好ましい。
R1、R2、R3、R4及びR5で示されるハロC1-C4アルキル基として好ましくは、1個以上のフッ素原子が置換したC1-C4アルキル基であり、より好ましくは1~5個のフッ素原子が置換したC1-C4アルキル基である。具体的にはトリフルオロメチル基、2,2,2-トリフルオロエチル基、1,1,2,2-テトラフルオロエチル基、ペンタフルオロエチル基などが挙げられ、より好ましくはトリフルオロメチル基である。
R1、R2、R3、R4及びR5で示されるハロC1-C4アルコキシ基として好ましくは、1個以上のフッ素原子が置換したC1-C4アルコキシ基であり、より好ましくは1~5個のフッ素原子が置換したC1-C4アルコキシ基である。具体的にはトリフルオロメトキシ基、2,2,2-トリフルオロエトキシ基、1,1,2,2-テトラフルオロエトキシ基、ペンタフルオロエトキシ基などが挙げられ、より好ましくはトリフルオロメトキシ基である。
X2はCHが最も好ましい。
W1、W2はカルボキシル基が好ましい。
Y1及びY2は互いに独立してメチレン基、O又はSであり、ただし同時にSでない)
である場合、具体的には下式で示す基が挙げられる。
nが3から5の整数であり;
W1及びW2がカルボキシル基であり;
Vが-CH2CH2-、-CH(CH3)O-又は-CH2O-であり;
Rが
nが4の整数であり;
W1及びW2がカルボキシル基であり;
Vが-CH2CH2-、-CH(CH3)O-又は-CH2O-であり;
Rが
当該好ましい態様において、Rが
1-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}インダン-5-カルボン酸(実施例1)
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例2)
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-6,7,8,9-テトラヒドロ-5H-ベンゾシクロヘプテン-2-カルボン酸(実施例3)
4-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}クロマン-7-カルボン酸(実施例4)
4-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}チオクロマン-7-カルボン酸(実施例5)
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロキノリン-2-カルボン酸(実施例6)
3-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-2,3-ジヒドロベンゾフラン-6-カルボン酸(実施例7)
4-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-イソクロマン-7-カルボン酸(実施例8)
5-{N-(4-カルボキシブチル)-N-[2-[2-(2-クロロベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例13)
5-{N-[2-[2-(4-ベンジルオキシベンジルオキシ)フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例14)
5-{N-[2-[2-(4-ベンジルスルファニルベンジルオキシ)フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例15)
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-フェニルスルファニルメチルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例17)
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-エチニルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例19)
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-シクロヘキシルエチニルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例22)
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-((E)-2-シクロヘキシルエテニル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例23)
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-シクロヘキシルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例24)
5-{N-(4-カルボキシブチル)-N-[2-[2-[トランス-4-(2-フェニルエチル)シクロヘキシルメトキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例26)
5-{N-(4-カルボキシブチル)-N-[2-[2-[シス-4-(2-フェニルエチル)シクロヘキシルメトキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例27)
5-{N-(4-カルボキシブチル)-N-[2-[2-(5,6,7,8-テトラヒドロナフタレン-1-イルメトキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例29)
5-{N-[2-[2-(3-tert-ブチルベンジルオキシ)フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例41)
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-シクロプロピルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例42)
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-イソプロピルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例43)
5-{N-[2-[2-[(1R)-1-(4-tert-ブチルフェニル)エトキシ]フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例45)
5-{N-(4-カルボキシブチル)-N-[2-[2-(インダン-2-イルメトキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸(実施例46)
さらに、本発明の一般式の(1)化合物は、同位元素(例、2H、3H、14C、35S、125I等)等でラベル化した化合物を包含する。
化合物(3)は、化合物(2)とニトロベンゼンスルホニル基導入剤を塩基の存在下又は非存在下、溶媒の非存在下又は不活性溶媒中で反応させることによって製造できる。使用されるニトロベンゼンスルホニル基導入剤は、例えば、2-ニトロベンゼンスルホニルクロリド、4-ニトロベンゼンスルホニルクロリドである。ニトロベンゼンスルホニル基導入剤の使用量は、化合物(2)に対して、通常1~5当量、好ましくは1~2当量である。使用される塩基は、例えば、アルカリ金属炭酸塩、アルカリ金属炭酸水素塩、アルカリ金属水酸化物又はトリエチルアミン、ジイソプロピルエチルアミン等の第3級有機アミンである。使用される溶媒は、例えば、ベンゼン、トルエン等の芳香族炭化水素類、アセトニトリル、プロピオニトリル、ブチロニトリル等のニトリル類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、ジエチルエーテル、テトラヒドロフラン(以下THFという)等のエーテル類、水又はこれらの混合物である。反応温度は、通常-30℃~40℃であり、好ましくは0℃~室温である。反応時間は通常0.5~24時間であり、好ましくは0.5~3時間である。
なお、化合物(2)は市販されているか、公知の方法で製造することができる。
化合物(5)は、化合物(3)と化合物(4)を脱水縮合剤の存在下、溶媒の非存在下又は不活性溶媒中で反応させることで製造できる。
化合物(4)の使用量は、化合物(3)に対して、通常1~3当量、好ましくは1~1.5当量である。使用される脱水縮合剤は、例えば、アゾジカルボン酸ジエチル、1,1’-アゾビス(N,N-ジメチルホルムアミド)等のアゾジカルボン酸化合物とトリフェニルホスフィン、トリ-n-ブチルホスフィン等のホスフィン類の組み合わせが挙げられる。脱水縮合剤の使用量は、化合物(3)に対して、通常、それぞれ1~3当量、好ましくは1~1.5当量である。使用される溶媒は、例えば、ベンゼン、トルエン等の芳香族炭化水素類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、ジエチルエーテル、THF等のエーテル類、N,N-ジメチルホルムアミド(以下DMFという)、ジメチルアセトアミド等のアミド類である。反応温度は、通常-30℃~40℃であり、好ましくは0℃~室温である。反応時間は通常1~48時間であり、好ましくは1~24時間である。
なお、化合物(4)は市販されているか、公知の方法で製造することができる。
化合物(6)は、化合物(5)を塩基及び脱保護試薬の存在下、溶媒の非存在下又は不活性溶媒中で反応させることによって製造できる。
使用される脱保護試薬は、例えば、n-プロピルアミン、ピロリジン等の第1級又は第2級有機アミン類;1-ドデカンチオール、チオフェノール、チオグリコール酸等のチオール類である。脱保護試薬の使用量は、化合物(5)に対して、通常1~5当量、好ましくは1~2当量である。使用される塩基は、例えば、アルカリ金属炭酸塩、アルカリ金属炭酸水素塩、アルカリ金属水素化物、アルカリ金属アルコキシド、第3級有機アミンである。使用される溶媒は、例えば、アセトニトリル、プロピオニトリル、ブチロニトリル等のニトリル類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、DMF、ジメチルアセトアミド等のアミド類又はこれらの混合物である。反応温度は、通常-30℃~40℃であり、好ましくは0℃~室温である。反応時間は通常1~48時間であり、好ましくは1~24時間である。
化合物(8)は、化合物(6)と化合物(7)を塩基と必要に応じて添加剤の存在下、溶媒の非存在下又は不活性溶媒中で反応させることによって製造できる。化合物(7)の使用量は、化合物(6)に対して、通常1~5当量、好ましくは1~3当量である。使用される塩基は、例えば、アルカリ金属炭酸塩、アルカリ金属炭酸水素塩、アルカリ金属水素化物、アルカリ金属アルコキシド、トリエチルアミン、ジイソプロピルエチルアミン、ピリジン等の有機アミンである。使用される添加剤としては、例えば、アルカリ金属ヨウ化物やテトラブチルアンモニウム塩、クラウンエーテル等の相間移動触媒である。使用される溶媒は、例えば、ベンゼン、トルエン等の芳香族炭化水素類、アセトニトリル、プロピオニトリル、ブチロニトリル等のニトリル類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、ケトン類、ジエチルエーテル、THF等のエーテル類、メタノール、エタノール、2-プロパノール等のアルコール類、DMF、ジメチルアセトアミド等のアミド類又はこれらの混合物である。反応温度は、通常室温~150℃であり、好ましくは室温~100℃である。反応時間は通常5~72時間であり、好ましくは8~48時間である。
化合物(9)は、化合物(8)においてU1及びU2の少なくとも一方がシアノ基である場合、シアノ基をテトラゾリル基に変換する公知の方法、例えば、アジ化物の存在下、不活性溶媒中で反応させる方法によって製造できる。
使用されるアジ化物は、例えば、アジ化金属塩、トリアルキルスズアジド、アンモニウムアジド、トリメチルシリルアジドである。本工程において、必要に応じて適宜、添加剤を使用することができる。使用される添加剤は、例えば、塩化アルミニウム、4級アンモニウム塩、マグネシウム塩、ジアルキルスズオキシド、塩化亜鉛である。使用される溶媒は、例えば、ベンゼン、トルエン等の芳香族炭化水素類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、ジエチルエーテル、THF等のエーテル類、DMF、ジメチルアセトアミド等のアミド類又はこれらの混合物である。反応温度は、通常室温~180℃であり、好ましくは50℃~120℃である。反応時間は通常5~72時間であり、好ましくは8~48時間である。
一般式(1)の化合物は、化合物(9)において、Q1及びQ2の少なくとも一方がCO2R6である場合に、化合物(9)を脱エステル化反応に付すことで製造できる。
脱エステル化反応は、エステル基(CO2R6)の種類に応じて、一般に有機合成化学の分野において周知の方法にしたがって行うことができる。例えば、塩基存在下で加水分解反応を行うことにより一般式(1)の化合物を製造することができる。
使用される塩基は、例えば、アルカリ金属炭酸塩、アルカリ金属水酸化物、アルカリ土類金属水酸化物又はアルカリ金属アルコキシドである。使用される溶媒は、ジエチルエーテル、THF等のエーテル類、メタノール、エタノール、2-プロパノール等のアルコール類、水又はこれらの混合物である。なお、本加水分解反応において、水は必須である。反応温度は、通常0℃~150℃であり、好ましくは室温~80℃である。反応時間は通常1~48時間であり、好ましくは3~24時間である。
化合物(12)は、化合物(11)を脱保護反応に付すことにより製造できる。
脱保護反応は、一般に有機合成化学の分野において周知の方法にしたがって行うことができる(例えば、T.W.Greene、P.G.Wuts、Greene’s Protective Groups in Organic Synthesis.Fourth Edition、2006年、John Wiley & Sons、Inc.に開示された方法)。
化合物(13)において、Eが脱離基である場合、化合物(8)は、化合物(12)と化合物(13)より上記工程4と同様の方法で製造することができる。
また、化合物(13)において、Eが水酸基である場合、化合物(8)は、化合物(12)と化合物(13)より上記工程2と同様の方法で製造することができる。
化合物(15)は、化合物(14)と酸化剤を不活性溶媒中で反応させることで製造できる。
使用される酸化剤は、例えば、1,1,1-トリアセトキシ-1,1-ジヒドロ-1,2-ベンズヨードキソール-3(1H)-オン(DMP)、1-ヒドロキシ-1,2-ベンズヨードキソール-3(1H)-オン-1-オキシド(IBX)等の高原子価ヨウ素試薬;アルミニウムアルコキシドとベンゾキノン、ベンゾフェノン、アセトン、ベンズアルデヒド等の水素受容体の組み合わせ;テトラプロピルアンモニウムパールテネイト(TPAP)又は2,2,6,6-テトラメチル-1-ピペリジニルオキシラジカル(TEMPO)と次亜塩素酸塩、亜臭素酸塩、N-クロロスクシンイミド等の共酸化剤の組み合わせ;ジメチルスルホキシド(以下DMSOという)とジシクロヘキシルカルボジイミド、五酸化リン、無水酢酸、塩化オキサリル等の親電子活性化試薬の組み合わせである。酸化剤の使用量は、化合物(14)に対して、通常1~10当量、好ましくは1~3当量である。本工程は必要に応じ、例えば、ピリジン又は炭酸水素ナトリウム等の塩基を添加することができる。使用される溶媒は、例えば、ベンゼン、トルエン等の芳香族炭化水素類、アセトニトリル、プロピオニトリル、ブチロニトリルなどのニトリル類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、ジエチルエーテル、THF等のエーテル類、酢酸エチル、酢酸プロピル、酢酸ブチル等のエステル類、DMF、ジメチルアセトアミド等のアミド類、DMSO、スルホラン等のスルホキシド類又はこれらの混合物である。反応温度は、通常-30℃~100℃であり、好ましくは0℃~室温である。反応時間は通常0.5~24時間であり、好ましくは1~8時間である。
化合物(6)は、化合物(15)と化合物(16)を酸の非存在下又は存在下、溶媒の非存在下又は不活性溶媒中で反応させ、最初にSchiff塩基を得て、次いでそれを還元剤の存在下、反応させることで製造できる。
化合物(16)の使用量は、化合物(15)に対して、通常1~3当量、好ましくは1~1.5当量である。使用される酸としては、例えば、塩酸、臭化水素酸、リン酸、硫酸等の無機酸、蟻酸、酢酸、プロピオン酸、メタンスルホン酸、p-トルエンスルホン酸等の有機酸である。使用される還元剤は、例えば、ボラン-テトラヒドロフラン錯体、水素化ホウ素ナトリウム、シアノ水素化ホウ素ナトリウム、トリアセトキシ水素化ホウ素ナトリウム等の水素化ホウ素化合物;水素化リチウムアルミニウム等の水素化アルミニウム化合物;水素が挙げられる。還元剤の使用量は、化合物(15)に対して、通常1~10当量、好ましくは1~5当量である。使用される溶媒は、例えば、ベンゼン、トルエン等の芳香族炭化水素類、クロロホルム、ジクロロメタン等のハロゲン化炭化水素類、ジエチルエーテル、THF等のエーテル類、酢酸エチル、酢酸プロピル、酢酸ブチル等のエステル類、メタノール、エタノール、2-プロパノール等のアルコール類又はこれらの混合物である。反応温度は、通常-78℃~150℃であり、好ましくは0℃~60℃である。反応時間は通常5分間~24時間であり、好ましくは30分間~4時間である。
なお、化合物(16)は市販されているか、公知の方法で製造することができる。
非経口投与のための本発明の医薬組成物としては、注射剤、坐剤、点眼剤、吸入剤、軟膏剤、ゲル剤、クリーム剤、貼付剤などが挙げられる。これらは、通常、1種以上の本発明化合物と、薬学上許容される希釈剤、賦形剤、担体などの添加剤を混合した医薬組成物として製造できる。また、安定化剤、防腐剤、溶解補助剤、保湿剤、保存剤、抗酸化剤、着香剤、ゲル化剤、中和剤、緩衝剤、等張剤、界面活性剤、着色剤、緩衝化剤、増粘剤、湿潤剤、充填剤、吸収促進剤、懸濁化剤、結合剤等の添加剤を含んでいてもよい。
また、本発明化合物を含有する医薬組成物には、本発明の目的に反しない限り、その他に利尿薬などの別種の薬効成分を適宜含有させてもよい。
2-メトキシメトキシベンズアルデヒド(16.4g)をニトロメタン(54mL)に懸濁し、酢酸アンモニウム(5.95g)を加え、80℃にて30分間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣を水に懸濁した後、酢酸エチルにて抽出した。有機層を飽和炭酸水素ナトリウム水溶液、飽和食塩水で順次洗浄した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をジオールシリカゲルカラムクロマトグラフィー(5%酢酸エチル/ヘキサン)にて精製し、表題化合物(11.6g)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:8.22(1H,d,J=13.6Hz),7.83(1H,d,J=13.6Hz),7.50-7.41(2H,m),7.23(1H,dd,J=8.4,0.9Hz),7.07(1H,ddd,J=8.4,7.5,1.1Hz),5.33(2H,s),3.52(3H,s).
水素化リチウムアルミニウム(6.30g)をテトラヒドロフラン(以降THF)(400mL)に懸濁し、氷冷下、参考例1(11.6g)のTHF(100mL)溶液を滴下し、加熱還流下、30分間攪拌した。氷冷下、硫酸ナトリウム10水和物(21.4g)を少しずつ加え、室温にて15分間攪拌した後、セライト濾過した。減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(20%メタノール/クロロホルム)にて精製し、表題化合物(6.73g)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.21-7.15(2H,m),7.09-7.06(1H,m),6.97-6.92(1H,m),5.21(2H,s),3.48(3H,s),2.95(2H,t,J=6.9Hz),2.79(2H,t,J=6.9Hz).
3-メルカプト安息香酸(10.0g)をメタノール(310mL)に懸濁し、硫酸(0.3mL)を加え、加熱還流下、24時間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣に水を加えた。飽和炭酸水素ナトリウム水溶液にて、pH8に調整した後、酢酸エチルで抽出し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(10%酢酸エチル/ヘキサン)にて精製し、表題化合物を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.95(1H,dd,J=2.0,1.5Hz),7.82(1H,ddd,J=7.7,1.5,1.3Hz),7.45(1H,ddd,J=7.9,2.0,1.3Hz),7.31(1H,dd,J=7.9,7.7Hz),3.91(3H,s),3.54(1H,s).
参考例3(10.3g)をアセトン(150mL)に溶解し、氷冷下、炭酸カリウム(17.0g)、3-ブロモプロピオン酸(10.3g)を加え、室温にて2.5時間攪拌した。減圧下溶媒を留去し、残渣を水に懸濁した。6mol/L塩酸でpH1に調整した後、酢酸エチルにて抽出した。有機層を水、飽和食塩水で順次洗浄した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(50%酢酸エチル/ヘキサン)にて精製し、表題化合物(14.5g)を白色粉末として得た。
1H-NMR(CDCl3)δ:8.03(1H,dd,J=1.8,1.7Hz),7.88(1H,ddd,J=7.9,1.7,1.1Hz),7.55(1H,ddd,J=7.7,1.8,1.1Hz),7.38(1H,dd,J=7.9,7.7Hz),3.92(3H,s),3.22(2H,t,J=7.3Hz),2.70(2H,t,J=7.3Hz).
参考例4(2.40g)をポリリン酸(13mL)に懸濁し、70℃にて15分間攪拌した。室温に冷却後、氷および水を加えた。酢酸エチルにて抽出し、有機層を飽和炭酸水素ナトリウム水溶液、飽和食塩水で順次洗浄した後、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(5%酢酸エチル/ヘキサン)にて精製し、表題化合物(0.36g)を無色油状物質として得た。
1H-NMR(CDCl3)δ:8.16(1H,d,J=8.2Hz),7.96(1H,d,J=1.6Hz),7.78(1H,dd,J=8.2,1.6Hz),3.94(3H,s),3.30-3.25(2H,m),3.04-3.00(2H,m).
5,6,7,8-テトラヒドロキノリン-5-オン(7.12g)をジクロロメタン(138mL)に溶解し、氷冷下、3-クロロ過安息香酸(14.5g)を加え、同温にて4時間攪拌した。飽和炭酸水素ナトリウム水溶液を加え、クロロホルムで希釈した後、セライト濾過にて不溶物を除去した。1mol/L水酸化ナトリウム水溶液を加えた後、クロロホルムで抽出し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をジエチルエーテルで懸濁し、濾取することにより、表題化合物(6.61g)を黄色粉末として得た。
1H-NMR(CDCl3)δ:8.44(1H,dd,J=6.4,0.9Hz),7.87(1H,dd,J=8.0,0.9Hz),7.32-7.25(1H,m),3.24(2H,t,J=6.2Hz),2.74-2.65(2H,m),2.28-2.17(2H,m)
参考例6(6.59g)をジクロロメタン(81mL)に溶解し、氷冷下、トリメチルシリルシアニド(17.9mL)、N,N-ジメチルカルバモイルクロリド(8.19mL)を加えた後、室温にて2.3時間、30℃にて4.5時間攪拌した。室温に冷却後、2mol/L水酸化ナトリウム水溶液を加え、激しく攪拌後、クロロホルムにて抽出した。無水硫酸ナトリウムで乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(4~30%酢酸エチル/ヘキサン)にて精製し、表題化合物(6.07g)を淡黄色粉末として得た。
1H-NMR(CDCl3)δ:8.40(1H,d,J=8.0Hz),7.68(1H,d,J=8.0Hz),3.21(2H,t,J=6.3Hz),2.79-2.72(2H,m),2.31-2.18(2H,m)
参考例7(6.05g)に対し、濃塩酸(70mL)を加え、加熱還流下、14時間攪拌した。室温に冷却後、減圧下濃塩酸を留去した。残渣を25%メタノール/クロロホルム溶液にて溶解後、飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をジイソプロピルエーテルにて懸濁し、濾取することにより、表題化合物(6.38g)を淡黄色粉末として得た。
1H-NMR(CDCl3)δ:8.53(1H,d,J=8.0Hz),8.19(1H,d,J=8.0Hz),3.23(2H,t,J=6.3Hz),2.81-2.75(2H,m),2.32-2.21(2H,m)
参考例8(980mg)より参考例3と同様の方法で、表題化合物(731mg)を淡黄色粉末として得た。
1H-NMR(CDCl3)δ:8.42(1H,d,J=8.1Hz),8.09(1H,d,J=8.1Hz),4.03(3H,s),3.27(2H,t,J=6.0Hz),2.78-2.72(2H,m),2.30-2.18(2H,m)
2,3-ジヒドロ-6-ヒドロキシ-3-オキソベンゾフラン(2.00g)をジクロロメタン(22mL)に溶解し、ピリジン(5.39mL)を加え、氷冷下、トリフルオロメタンスルホン酸無水物(2.69mL)を滴下した。同温にて2時間攪拌後、減圧下溶媒を留去した。残渣を酢酸エチルにて希釈した後、水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(5~20%酢酸エチル/ヘキサン)で精製し、ヘキサン/ジイソプロピルエーテル混合溶液にて懸濁し、濾取することにより、表題化合物(1.84g)を黄色粉末として得た。
1H-NMR(CDCl3)δ:7.77(1H,d,J=8.4Hz),7.10(1H,d,J=2.0Hz),7.02(1H,dd,J=8.4,2.0Hz),4.73(2H,s)
参考例10(940mg)をTHF(15mL)に溶解し、氷冷下、水素化ホウ素ナトリウム(146mg)を数回に分けて加え、同温にて1.5時間攪拌した。氷冷下、飽和塩化アンモニウム水溶液を加えた後、酢酸エチルにて抽出した。有機層を飽和食塩水にて洗浄し、無水硫酸ナトリウムで乾燥後、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(6~35%酢酸エチル/ヘキサン)にて精製し、表題化合物(785mg)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.47(1H,d,J=8.2Hz),6.86(1H,dd,J=8.2,2.2Hz),6.80(1H,d,J=2.2Hz),5.40(1H,ddd,J=6.8,6.8,2.8Hz),4.66(1H,dd,J=10.9,6.8Hz),4.53(1H,dd,J=10.9,2.8Hz),2.01(1H,d,J=6.8Hz).
参考例11(155mg)をDMF(3.0mL)に溶解し、メタノール(0.40mL)、トリエチルアミン(0.38mL)、1,3-ビス(ジフェニルホスフィノ)プロパン(11.2mg)、酢酸パラジウム(II)(6.10mg)を加え、一酸化炭素雰囲気下、常圧、60℃にて3時間攪拌した。室温に冷却後、水で希釈し、ジエチルエーテルにて抽出した。有機層を水、飽和食塩水で順次洗浄し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(33%酢酸エチル/ヘキサン)にて精製し、表題化合物(75.0mg)を薄紅色粉末として得た。
1H-NMR(CDCl3)δ:7.66(1H,dd,J=7.7,1.5Hz),7.52(1H,d,J=1.5Hz),7.47(1H,d,J=7.7Hz),5.41(1H,ddd,J=6.8,6.8,2.9Hz),4.62(1H,dd,J=10.8,6.8Hz),4.50(1H,dd,J=10.8,2.9Hz),3.91(3H,s),2.05(1H,d,J=6.8Hz)
7-ヒドロキシイソクロマン-4-オン(1.00g)より参考例10と同様の方法で、表題化合物(1.70g)を白色粉末として得た。
1H-NMR(CDCl3)δ:8.16(1H,d,J=8.6Hz),7.32(1H,dd,J=8.6,2.4Hz),7.18(1H,d,J=2.4Hz),4.93(2H,s),4.40(2H,s).
参考例13(1.50g)より参考例12と同様の方法で、表題化合物(588mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:8.13-8.04(2H,m),7.92(1H,s),4.94(2H,s),4.41(2H,s),3.96(3H,s).
5-オキソ-6,7,8,9-テトラヒドロ-5H-ベンゾシクロヘプテン-2-カルボン酸メチル(523mg)より参考例11と同様の方法で、表題化合物(526mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:7.88(1H,dd,J=8.1,1.6Hz),7.77(1H,d,J=1.6Hz),7.56(1H,d,J=8.1Hz),5.01-4.96(1H,m),3.90(3H,s),2.99-2.91(1H,m),2.79-2.71(1H,m),2.08-1.97(2H,m),1.89(1H,d,J=4.0Hz),1.85-1.68(3H,m),1.46-1.33(1H,m).
4-(フェニルスルファニルメチル)安息香酸メチル(1.07g)をTHF(14mL)に溶解し、氷冷下、水素化リチウムアルミニウム(200mg)を少量ずつ加え、同温にて40分間攪拌した。氷冷下、硫酸ナトリウム10水和物を少しずつ加えた後、セライト濾過し、減圧下溶媒を留去した。残渣をヘキサンにて懸濁し、濾取することにより、表題化合物(910mg)を白色粉末として得た。
1H-NMR(DMSO-D6)δ:7.34-7.12(9H,m),5.10(1H,t,J=5.7Hz),4.44(2H,d,J=5.7Hz),4.21(2H,s)
N-フェニル-2-ニトロベンゼンスルホンアミド(1.95g)をDMF(15mL)に溶解し、氷冷下、炭酸カリウム(1.16g)、2-(4-クロロメチルベンジルオキシ)テトラヒドロ-2H-ピラン(2.02g)のDMF(3mL)溶液を加え、40℃にて18時間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣を水に懸濁し、酢酸エチルにて抽出した。有機層を水、飽和食塩水で順次洗浄した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(33%酢酸エチル/ヘキサン)にて精製し、表題化合物(3.29g)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.66-7.64(2H,m),7.54-7.42(2H,m),7.27-7.17(7H,m),7.12-7.06(2H,m),4.95(2H,s),4.73(1H,d,J=12.1Hz),4.68-4.66(1H,m),4.45(1H,d,J=12.1Hz),3.92-3.85(1H,m),3.54-3.49(1H,m),1.89-1.51(6H,m).
参考例20(3.37g)をメタノール(35mL)に溶解し、p-トルエンスルホン酸1水和物(133mg)を加え、室温にて30分間攪拌した。減圧下溶媒を留去し、残渣を酢酸エチルに溶解した。有機層を飽和炭酸水素ナトリウム水溶液、飽和食塩水にて順次洗浄した後、無水硫酸ナトリウムで乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(50%酢酸エチル/ヘキサン)にて精製し、表題化合物(2.57g)を淡黄色粉末として得た。
1H-NMR(CDCl3)δ:7.66-7.65(2H,m),7.54-7.43(2H,m),7.26-7.17(7H,m),7.10-7.06(2H,m),4.95(2H,s),4.64(2H,d,J=5.1Hz),1.63(1H,t,J=5.1Hz).
4-ヨードベンジルアルコール(1.00g)をDMF(17mL)に溶解し、ヨウ化銅(I)(97.7mg)、トリエチルアミン(0.89mL)、3-メチル-1-ブチン(1.27mL)を加え、アルゴン雰囲気下10分間攪拌した。ついで、ビス(トリフェニルホスフィン)パラジウム(II)クロリド(300mg)を加え、アルゴン雰囲気下室温にて4.3時間攪拌した。セライト濾過後、酢酸エチルで洗浄し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(6~40%酢酸エチル/ヘキサン)にて精製し、表題化合物を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.38(2H,d,J=8.3Hz),7.27(2H,d,J=8.3Hz),4.67(2H,d,J=5.5Hz),2.85-2.70(1H,m),1.66(1H,t,J=5.5Hz),1.26(6H,d,J=7.0Hz).
4-ヨードベンジルアルコール(2.34g)をDMF(40mL)に溶解し、ビニルシクロヘキサン(1.32g)、トリエチルアミン(1.81mL)、ビス(トリフェニルホスフィン)パラジウム(II)クロリド(700mg)を加え、80℃にて23時間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(8~30%酢酸エチル/ヘキサン)にて精製し、表題化合物(672mg)を黄色固体として得た。
1H-NMR(CDCl3)δ:7.34-7.19(4H,m),6.29(1H,d,J=16.0Hz),6.13(1H,dd,J=16.0,6.8Hz),4.67-4.56(3H,m),2.15-2.00(1H,m),1.82-1.51(4H,m),1.37-1.04(6H,m)
参考例25(283mg)をメタノール(7.0mL)に溶解し、パラジウム-フィブロイン(57.0mg)を加え、水素雰囲気下、常圧、室温にて45分間攪拌した。セライト濾過後、メタノールで洗浄し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(5~35%酢酸エチル/ヘキサン)にて精製し、表題化合物(206mg)を黄色粉末として得た。
1H-NMR(CDCl3)δ:7.27(2H,d,J=8.1Hz),7.17(2H,d,J=8.1Hz),4.66(2H,d,J=5.9Hz),2.66-2.57(2H,m),1.82-1.60(5H,m),1.57-1.44(3H,m),1.32-1.10(4H,m),1.01-0.85(2H,m)
トランス-4-ビニルシクロヘキサンカルボン酸メチル(492mg)より参考例25と同様の方法で、表題化合物(326mg)を茶色固体として得た。
1H-NMR(CDCl3)δ:7.39-7.12(5H,m),6.36(1H,d,J=15.9Hz),6.14(1H,dd,J=15.9,7.0Hz),3.68(3H,s),2.35-2.21(1H,m),2.19-1.99(3H,m),1.97-1.87(2H,m),1.60-1.43(2H,m),1.30-1.14(2H,m)
参考例27(120mg)より参考例19と同様の方法で、表題化合物(99.0mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:7.38-7.22(4H,m),7.21-7.14(1H,m),6.36(1H,d,J=16.0Hz),6.16(1H,dd,J=16.0,7.0Hz),3.48(2H,d,J=6.2Hz),2.17-2.01(1H,m),1.95-1.79(4H,m),1.64-1.31(2H,m),1.30-1.15(2H,m),1.12-0.96(2H,m)
参考例27(200mg)をメタノール(5.0mL)に溶解し、5%パラジウム-炭素(80.0mg)を加え、水素雰囲気下、3気圧、室温にて7.3時間攪拌した。セライト濾過後、メタノールで洗浄し、減圧下溶媒を留去した。残渣を酢酸エチルにて希釈した後、飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(5%酢酸エチル/ヘキサン)にて精製し、表題化合物(192mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.31-7.23(2H,m),7.21-7.11(3H,m),3.66(3H,s),2.66-2.58(2H,m),2.25(1H,tt,J=12.3,3.5Hz),2.03-1.93(2H,m),1.92-1.83(2H,m),1.57-1.20(5H,m),0.97(2H,ddd,J=16.3,13.4,3.5Hz)
参考例29(190mg)より参考例19と同様の方法で、表題化合物(166mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.31-7.23(2H,m),7.21-7.12(3H,m),3.45(2H,d,J=6.4Hz),2.66-2.59(2H,m),1.91-1.74(4H,m),1.60-1.16(5H,m),1.06-0.82(4H,m).
臭化ベンジルトリフェニルホスホニウム(2.94g)をTHF(23.0mL)に溶解し、-20℃で、カリウムtert-ブトキシド(1.07g)を少しずつ加え、同温にて1時間攪拌した。ついで、シス-4-ホルミルシクロヘキサンカルボン酸メチル(1.00g)のTHF(6.0mL)溶液を35分間かけて滴下し、同温にて1.6時間攪拌した。室温に昇温後、水を加え攪拌した後、トルエンにて抽出し、有機層を水、飽和食塩水で順次洗浄した。無水硫酸ナトリウムで乾燥後、減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(9%酢酸エチル/ヘキサン)にて精製し、表題化合物(268mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.37-7.15(5H,m),6.37(1H,d,J=16.6Hz),6.22(1H,dd,J=16.6,6.6Hz),3.69(3H,s),2.62-2.50(1H,m),2.38-2.24(1H,m),2.10-2.00(3H,m),1.76-1.42(5H,m)
参考例31(268mg)より参考例29と同様の方法で、表題化合物(248mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.31-7.23(2H,m),7.20-7.13(3H,m),3.68(3H,s),2.64-2.48(3H,m),2.05-1.92(2H,m),1.67-1.23(9H,m)
参考例32(248mg)より参考例19と同様の方法で、表題化合物(208mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.31-7.24(2H,m),7.21-7.14(3H,m),3.54(2H,t,J=5.3Hz),2.64-2.56(2H,m),1.72-1.32(12H,m),1.25-1.18(1H,m)
6-ブロモ-チオクロマン(1.00g)をTHF(15.0mL)に溶解し、-78℃にて、2.69mol/L n-ブチルリチウム/ヘキサン溶液(3.24mL)を滴下し、同温にて1時間攪拌した。同温にてDMF(0.71mL)を加えた後、室温まで昇温しながら16時間攪拌した。飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出後、有機層を飽和食塩水にて洗浄した。無水硫酸ナトリウムで乾燥後、減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(2~15%酢酸エチル/ヘキサン)にて精製し、表題化合物(342mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:9.85(1H,s),7.57-7.48(2H,m),7.21(1H,d,J=8.1Hz),3.12-3.05(2H,m),2.89(2H,t,J=6.1Hz),2.20-2.10(2H,m)
参考例34(340mg)をメタノール(10mL)に溶解し、氷冷下、水素化ホウ素ナトリウム(91.2mg)を数回に分けて加え、同温にて1時間攪拌した。氷冷下、飽和塩化アンモニウム水溶液を加え攪拌し、減圧下溶媒を留去した。酢酸エチルで希釈した後、水、飽和食塩水にて順次洗浄した。無水硫酸ナトリウムで乾燥後、減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(6~50%酢酸エチル/ヘキサン)にて精製し、表題化合物を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.11-7.01(3H,m),4.58(2H,d,J=5.1Hz),3.06-2.98(2H,m),2.81(2H,t,J=6.1Hz),2.17-2.05(2H,m)
トリフルオロメタンスルホン酸 5-オキソ-5,6,7,8-テトラヒドロナフタレン-2-イル(1.47g)より参考例22と同様の方法で、表題化合物(1.10g)を黄色粉末として得た。
1H-NMR(CDCl3)δ:8.01(1H,d,J=7.9Hz),7.56-7.51(2H,m),7.46-7.34(5H,m),2.96(2H,t,J=6.0Hz),2.67(2H,t,J=6.6Hz),2.15(2H,tt,J=6.6,6.0Hz).
参考例36(493mg)より参考例11と同様の方法で、表題化合物(485mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:7.58-7.48(2H,m),7.43-7.29(6H,m),4.79-4.75(1H,m),2.87-2.66(2H,m),2.08-1.73(4H,m),1.59(1H,brs).
参考例37(482mg)より参考例26と同様の方法で、表題化合物(423mg)を無色油状物質として得た。
1H-NMR(CDCl3)δ:7.37-7.17(6H,m),7.05(1H,dd,J=7.7,1.6Hz),6.95(1H,d,J=1.6Hz),4.80-4.75(1H,m),2.95-2.64(6H,m),2.01-1.72(4H,m),1.63(1H,d,J=6.2Hz).
参考例19(77.0mg)をジクロロメタン(2.0mL)に溶解し、塩化チオニル(30μL)を加え、1.8時間攪拌した。減圧下溶媒並びに試薬を留去し、表題化合物の粗生成物を白色アモルファスで得た。
1H-NMR(CDCl3)δ:7.34-7.14(9H,m),4.56(2H,s),4.10(2H,s)
2-(2-ブロモフェニル)エチルアルコール(3.42g)及び4-ビニル-トランス-スチルベン(4.21g)より参考例25と同様の方法で、表題化合物(4.80g)を黄色固体として得た。
1H-NMR(DMSO-D6)δ:7.69-7.60(7H,m),7.50(1H,d,J=16.2Hz),7.41-7.35(2H,m),7.29-7.20(6H,m),7.12(1H,d,J=16.2Hz),4.73(1H,t,J=5.7Hz),3.57(2H,td,J=7.0,5.7Hz),2.93(2H,t,J=7.0Hz).
参考例47(4.80g)より参考例29と同様の方法で、表題化合物(4.56g)を無色油状物質として得た。
1H-NMR(DMSO-D6)δ:7.36-7.22(4H,m),7.20-7.08(9H,m),4.69(1H,t,J=5.5Hz),3.55(2H,td,J=7.1,5.5Hz),2.86-2.80(4H,m),2.84(2H,t,J=7.1Hz),2.79-2.74(2H,m),2.75(2H,t,J=6.3Hz).
参考例48(496mg)をDMSO(10mL)に溶解し、IBX(840mg)を加え、室温にて1.5時間撹拌した。酢酸エチル、水を順次加え、室温にて1時間撹拌した。沈殿物を濾過し、酢酸エチルにて洗浄した。分液操作後、有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥後、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(10~30%酢酸エチル/ヘキサン)にて精製し、表題化合物(422mg)を無色油状物質として得た。
1H-NMR(DMSO-D6)δ:9.62(1H,t,J=1.7Hz),7.27-7.22(5H,m),7.20-7.15(4H,m),7.13-7.07(4H,m),3.77(2H,d,J=1.7Hz),2.83(4H,s),2.74-2.72(4H,m).
アルゴン雰囲気下、5-アミノ-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸メチル塩酸塩(311mg)をジクロロメタン(26mL)に溶解し、トリエチルアミン(0.18mL)を加え、室温にて5分間撹拌した。参考例49(422mg)、酢酸(0.11mL)を順次加え、同温にて10分間撹拌した。ついで、氷冷下、トリアセトキシ水素化ホウ素ナトリウム(681mg)を加え、室温にて2時間撹拌した。飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで抽出した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(30~70%酢酸エチル/ヘキサン)にて精製し、表題化合物(607mg)を無色油状物質として得た。
1H-NMR(DMSO-D6)δ:7.68-7.63(2H,m),7.50(1H,d,J=8.4Hz),7.29-7.08(13H,m),3.80(3H,s),3.73(1H,brs),2.85-2.79(7H,m),2.76-2.75(8H,m),1.93-1.56(4H,m).
参考例2(6.72g)をジクロロメタン(186mL)に溶解し、氷冷下、トリエチルアミン(5.67mL)、2-ニトロベンゼンスルホニルクロリド(10.1g)を加え、同温にて1時間攪拌した。減圧下溶媒を留去し、残渣を酢酸エチルに懸濁した後、水、飽和食塩水にて順次洗浄し、無水硫酸ナトリウムで乾燥した。減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(20%酢酸エチル/ヘキサン)にて精製し、表題化合物(11.0g)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:8.10-8.05(1H,m),7.83-7.79(1H,m),7.72-7.66(2H,m),7.18-7.12(1H,m),7.04-7.01(2H,m),6.86(1H,ddd,J=8.6,7.5,1.3Hz),5.51(1H,t,J=5.5Hz),5.19(2H,s),3.46(3H,s),3.39(2H,td,J=6.9,5.5Hz),2.87(2H,t,J=6.9Hz).
2-{2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル}エチルアミン(1.83g)から、参考例51と同様の方法により表題化合物(2.47g)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.97(1H,dd,J=7.6,1.7Hz),7.76(1H,dd,J=7.3,1.8Hz),7.66-7.55(2H,m),7.37-7.12(10H,m),7.01(1H,dd,J=7.3,1.6Hz),6.86-6.78(2H,m),5.43(1H,t,J=5.7Hz),5.00(2H,s),3.40(2H,td,J=6.8,5.7Hz),2.94(4H,s),2.86(2H,t,J=6.8Hz).
参考例51(733mg)をトルエン(10mL)に溶解し、氷冷下、1-ヒドロキシインダン-5-カルボン酸メチル(577mg)、トリ-n-ブチルホスフィン(0.75mL)、1,1’-アゾビス(N,N-ジメチルホルムアミド)(517mg)を加え、室温にて14.5時間攪拌した。減圧下溶媒を留去し、残渣を酢酸エチルに再溶解した。水、飽和食塩水で順次洗浄した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(20%酢酸エチル/ヘキサン)にて精製し、表題化合物を黄色油状物質として得た。
1H-NMR(CDCl3)δ:8.19-8.16(1H,m),7.92(1H,s),7.86-7.83(1H,m),7.74-7.66(3H,m),7.29-7.25(1H,m),7.14-7.08(1H,m),6.97-6.93(2H,m),6.85(1H,ddd,J=8.4,7.4,1.1Hz),5.66-5.61(1H,m),5.00(1H,d,J=6.8Hz),4.95(1H,d,J=6.8Hz),3.90(3H,s),3.38-3.19(2H,m),3.27(3H,s),3.13-2.78(3H,m),2.67-2.49(2H,m),2.23-2.11(1H,m).
参考例53(1.08g)をDMF(10mL)に溶解し、氷冷下、チオフェノール(0.41mL)、炭酸カリウム(553mg)を加えて、室温にて18時間攪拌した。水で希釈した後、ジエチルエーテルにて抽出し、有機層を水、飽和食塩水で順次洗浄した。無水硫酸ナトリウムにて乾燥後、減圧下溶媒を留去し、残渣をアミンシリカゲルカラムクロマトグラフィー(67%酢酸エチル/ヘキサン)にて精製し、表題化合物(638mg)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.88-7.85(2H,m),7.32(1H,d,J=7.7Hz),7.20-7.15(2H,m),7.08(1H,dd,J=8.6,1.1Hz),6.95(1H,ddd,J=8.4,7.5,1.1Hz),5.20(2H,s),4.30(1H,t,J=7.0Hz),3.90(3H,s),3.45(3H,s),3.05-2.77(6H,m),2.49-2.38(1H,m),1.91-1.79(1H,m).
参考例62(636mg)をDMF(9.0mL)に溶解し、炭酸カリウム(495mg)、5-ブロモ吉草酸メチル(0.51mL)を加え、95℃にて18.5時間加熱した。室温に冷却後、減圧下溶媒を留去後、残渣を水で懸濁し、酢酸エチルにて抽出した。有機層を水、飽和食塩水で順次洗浄した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(17%酢酸エチル/ヘキサン)にて精製し、表題化合物(568mg)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.84-7.82(2H,m),7.27-7.24(1H,m),7.17-7.07(2H,m),7.01(1H,dd,J=8.2,1.0Hz),6.90(1H,ddd,J=8.4,7.3,1.1Hz),5.07(2H,s),4.57(1H,t,J=8.0Hz),3.90(3H,s),3.66(3H,s),3.35(3H,s),2.97-2.56(6H,m),2.52(2H,t,J=6.9Hz),2.29(2H,t,J=7.2Hz),2.23-2.13(1H,m),2.02-1.89(1H,m),1.74-1.48(4H,m).
参考例71(564mg)をTHF(5.5mL)、メタノール(0.5mL)に溶解し、濃塩酸(0.6mL)を加え、室温にて22時間攪拌した。減圧下溶媒を留去後、残渣を水で希釈し、氷冷下、飽和炭酸水素ナトリウム水溶液にてpH8に調整した。酢酸エチルにて抽出した後、有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(20%酢酸エチル/ヘキサン)にて精製し、表題化合物(304mg)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:12.19(1H,s),7.86-7.81(2H,m),7.53(1H,d,J=8.1Hz),7.14(1H,ddd,J=9.7,8.1,1.9Hz),6.96-6.91(2H,m),6.74(1H,ddd,J=8.4,7.2,1.3Hz),4.76(1H,t,J=7.4Hz),3.89(3H,s),3.62(3H,s),3.04-2.54(7H,m),2.43-2.22(4H,m),2.10-1.98(1H,m),1.61-1.51(4H,m).
参考例82(298mg)をアセトニトリル(2.8mL)に溶解し、4-(2-フェニルエチル)ベンジルクロリド(194mg)、炭酸カリウム(145mg)を加え、加熱還流下、18時間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣を水に懸濁し、酢酸エチルにて抽出した。有機層を飽和食塩水で洗浄した後、無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(17%酢酸エチル/ヘキサン)にて精製し、表題化合物(393mg)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.81-7.78(2H,m),7.31-7.09(12H,m),6.90-6.85(2H,m),4.97(1H,d,J=13.2Hz),4.93(1H,d,J=13.2Hz),4.51(1H,t,J=8.1Hz),3.88(3H,s),3.64(3H,s),2.94-2.82(6H,m),2.76-2.59(4H,m),2.42(2H,t,J=6.9Hz),2.21(2H,t,J=7.3Hz),2.14-2.06(1H,m),1.97-1.84(1H,m),1.65-1.39(4H,m).
参考例83(175mg)および参考例28(95.0mg)より参考例53と同様の方法で、表題化合物(132mg)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.76-7.63(3H,m),7.39-7.23(4H,m),7.23-7.10(2H,m),7.07(1H,dd,J=7.3,1.6Hz),6.84(1H,ddd,J=8.4,7.3,1.1Hz),6.77(1H,dd,J=8.3,1.1Hz),6.37(1H,d,J=16.1Hz),6.17(1H,dd,J=16.1,7.0Hz),4.05-3.95(1H,m),3.89(3H,s),3.73-3.65(2H,m),3.64(3H,s),2.94-2.59(6H,m),2.51(2H,t,J=7.0Hz),2.27(2H,t,J=7.5Hz),2.15-1.95(3H,m),1.95-1.83(3H,m),1.76-1.38(8H,m),1.33-1.03(4H,m).
参考例96(172mg)より参考例62と同様の方法で、表題化合物を黄色油状物質として得た。
1H-NMR(CDCl3)δ:7.69-7.60(3H,m),7.35-7.08(8H,m),6.89-6.84(2H,m),6.74-6.64(3H,m),4.94(2H,s),4.33(2H,s),3.97-3.91(1H,m),3.87(3H,s),3.64(3H,s),2.90-2.60(6H,m),2.44(2H,t,J=7.0Hz),2.19(2H,t,J=7.3Hz),2.00-1.91(2H,m),1.63-1.38(7H,m).
参考例81(102mg)をトルエン(5.0mL)に懸濁し、トリメチルスズアジド(175mg)を加え、加熱還流下、44時間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣をメタノール(2mL)に溶解し、室温にて15分間攪拌した。ついで、減圧下溶媒を留去し、残渣をシリカゲルカラムクロマトグラフィー(2%メタノール/クロロホルム)にて精製し、表題化合物(84mg)を黄色アモルファスとして得た。
1H-NMR(CDCl3)δ:7.70-7.69(3H,m),7.30-7.06(11H,m),6.91-6.83(2H,m),4.92(2H,s),4.26(1H,dd,J=8.8,5.9Hz),4.11(1H,s),3.87(3H,s),2.98-2.69(12H,m),2.54(2H,t,J=6.1Hz),2.02-1.84(2H,m),1.75-1.48(6H,m).
5,6,7,8-テトラヒドロイソキノリン-3,8-ジオン(970mg)より参考例10と同様の方法で、表題化合物(1.53g)を黄色油状物質として得た。
1H-NMR(CDCl3)δ:8.96(1H,s),7.07(1H,s),3.05(2H,t,J=6.1Hz),2.76-2.70(2H,m),2.26-2.16(2H,m).
参考例118(1.53g)をDMF(12mL)に溶解し、アルゴン雰囲気下、シアン化亜鉛(487mg)、テトラキス(トリフェニルホスフィン)パラジウム(0)(299mg)を加え、80℃にて3時間攪拌した。セライト濾過後、酢酸エチルにて希釈し、飽和食塩水で洗浄した。無水硫酸ナトリウムにて乾燥し、減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(8~16%酢酸エチル/ヘキサン)で精製し、ヘキサン/ジイソプロピルエーテル混合溶液にて懸濁し、濾取することにより、表題化合物(680mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:9.20(1H,s),7.64-7.62(1H,m),3.03(2H,t,J=6.0Hz),2.79-2.72(2H,m),2.28-2.18(2H,m).
参考例119(672mg)より参考例8と同様の方法で、表題化合物(685mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:9.14(1H,s),8.15(1H,s),3.10(2H,t,J=6.0Hz),2.81-2.73(2H,m),2.29-2.19(2H,m).
参考例120(540mg)をクロロホルム(14mL)に溶解し、氷冷下、ジアゾメタン/ジエチルエーテル溶液を反応が完結するまで加えた。反応液が無色になるまで酢酸を加えた後、減圧下溶媒を留去した。残渣をシリカゲルカラムクロマトグラフィー(8~80%酢酸エチル/ヘキサン)で精製し、表題化合物(360mg)を白色粉末として得た。
1H-NMR(CDCl3)δ:9.24(1H,s),8.06-8.04(1H,m),4.03(3H,s),3.05(2H,t,J=6.1Hz),2.78-2.70(2H,m),2.27-2.16(2H,m).
参考例121(432mg)より参考例11と同様の方法で、表題化合物(448mg)を定量的に得た。
1H-NMR(CDCl3)δ:8.78(1H,s),7.88(1H,s),4.96-4.86(1H,m),4.00(3H,s),2.96-2.70(2H,m),2.15-1.76(5H,m).
参考例85(391mg)をTHF(1.0mL)、メタノール(2.1mL)に溶解し、2.5mol/L水酸化ナトリウム水溶液(1.0mL)を加え、50℃にて1.5時間攪拌した。室温に冷却後、減圧下溶媒を留去し、残渣を水に再溶解した。2mol/L塩酸にてpH4に調整した後、クロロホルムで抽出し、無水硫酸ナトリウムにて乾燥した。減圧下溶媒を留去した後、残渣をシリカゲルカラムクロマトグラフィー(10%~20%メタノール/クロロホルム)にて精製し、表題化合物を無色アモルファスとして得た。
1H-NMR(CD3OD)δ:7.92-7.87(2H,m),7.50(1H,d,J=7.9Hz),7.30-7.09(11H,m),7.03(1H,d,J=7.5Hz),6.90(1H,ddd,J=8.2,7.3,0.7Hz),5.11(1H,dd,J=8.2,4.9Hz),4.99(2H,s),3.19-2.82(12H,m),2.41-2.14(4H,m),1.78-1.46(4H,m).
ESI-MS Found:m/z 592(M+H)+
試験にはヒトsGC αサブユニット及びβサブユニット、マウス環状ヌクレオチド感受性チャネル(CNGA2)を安定発現させたチャイニーズハムスター卵巣細胞(CHO-K1細胞)を用いた。
ヒトsGC及びマウスCNGA2が安定発現したCHO-K1細胞は37℃で10%(v/v)ウシ胎仔血清(FBS)、ペニシリン(100U/mL)、ストレプトマイシン(100μg/mL)、G418(250μg/mL)、ゼオシン(250μg/mL)を加えたF-12培地にて培養した。細胞は培養液で懸濁し、96穴プレ-トに播種した後、37℃で24時間培養した。アッセイバッファー1(140mmol/L塩化ナトリウム、5mmol/L塩化カリウム、0.5mmol/L塩化マグネシウム、0.01mmol/L塩化カルシウム、10mmol/Lグルコース、0.4mmol/L硫酸マグネシウム、10mmol/L 4-(2-ヒドロキシエチル)ピペラジン-1-イルエタンスルホン酸、125μmol/Lスルフィンピラゾン、pH7.4)にて洗浄した後、蛍光Ca2+指示薬であるFura2-AMを5μmol/Lの濃度でアッセイバッファー1に溶解した指示薬溶液を加え、37℃で60分間培養した。培養液を除き、アッセイバッファー1にて洗浄した後、試験化合物溶液を加え、室温で10分間培養した。蛍光測定装置(FlexStation II、Molecular Devices社)にプレートを設置し、励起波長340nm及び380nm、検出波長510nmとして、各励起波長より得られる蛍光強度比として細胞内カルシウム濃度を測定した。
なお、試験化合物溶液は、各試験化合物を10mmol/LとなるようにDMSOに溶解した後、試験濃度が10μmol/Lとなるようにアッセイバッファー2(140mmol/L塩化ナトリウム、5mmol/L塩化カリウム、0.5mmol/L塩化マグネシウム、1mmol/L塩化カルシウム、10mmol/Lグルコース、0.4mmol/L硫酸マグネシウム、10mmol/L 4-(2-ヒドロキシエチル)ピペラジン-1-イルエタンスルホン酸、125μmol/Lスルフィンピラゾン、100μmol/Lイソブチルメチルキサンチン、10μmol/L 1H-[1,2,4]-オキサジアゾール[4,3-a]キノキサリン-1-オン(以下ODQ)、pH7.4)により希釈し、調製した。ODQ不含時の評価の場合、アッセイバッファー2よりODQを除外し、同様の評価を実施した。コントロール溶液には試験化合物溶液の代わりにDMSO希釈溶液を用いた。
試験化合物の活性は、コントロール溶液添加時のsGC活性に対する試験化合物溶液添加時のsGC活性の増加率(%)として、試験化合物を添加した際の蛍光強度比をコントロール溶液の蛍光強度比で除し、コントロール溶液添加時のsGC活性(100%)を減じることで算出した。
試験結果を表38及び表39に示す。
表38及び表39に示すとおり、本発明化合物はいずれもODQ存在下でsGC活性を顕著に増加させ、ヘム非依存性の直接的sGC活性化剤であることが明らかとなった。また、本発明化合物は、シナシグアトと比較してODQ存在下、非存在下いずれの場合においてもEmaxが大きく、シナシグアトと比較して優れたsGC活性化作用を有することが明らかとなった。
さらに代表的な化合物について、試験例1と同様の方法により、それぞれ0.0001、0.001、0.003、0.01、0.03、0.1、1、10μmol/Lの試験濃度における活性を測定した。
各試験化合物のsGC活性化作用におけるヘム非依存性作用の程度は、上記によって作成した濃度-活性曲線から求めたEC50について、ODQ不在時のEC50をODQ存在時のEC50で除することにより求めた。すなわち、このEC50比が小さいほど、ODQの存在の有無によるsGC活性化作用の変化が少なく、よりヘム非依存的であると言える。
EC50値はそれぞれ0.0001、0.001、0.003、0.01、0.03、0.1、1、10μmol/Lの濃度における被験化合物の活性を測定し、Assay Explorer(アクセルリス社)にて4パラメーターロジスティックモデルにより算出した。
試験結果を表40に示す。
本発明の代表的な化合物について、下記の試験例により、血管弛緩作用を試験した。試験では、ラット(雄性、SD)をペントバルビタール(30 mg/kg)麻酔下で心臓上部から瀉血し、腹部大動脈を摘出した。腹部大動脈は、氷冷Krebs-Henseleit液(KH液)(118mmol/L塩化ナトリウム、4.7mmol/L塩化カリウム、1.2mmol/L硫酸マグネシウム、1.2mmol/Lリン酸二水素カリウム、25mmol/L炭酸水素ナトリウム、2.5mmol/L塩化カルシウム、10mmol/Lグルコース、pH7.4)中で血管周囲に付着した結合組織を除去した。その後、長さ2mmのリング標本を作製し、KH液を満たした5mL器官浴に固定した。KH液は37℃に維持し、95%O2及び5%CO2混合ガスを通気した。標本は静止張力1gで1時間安定化させた。この間、KH液は2回交換した。標本の張力は、ピックアップ、増幅器を介してマルチチャネルレコーダーに記録した。標本安定化後、1μmol/L フェニレフリン(Phe)にて収縮を惹起させ、各化合物の累積投与(0.001、0.01、0.03、0.1、0.3、1、3、10、30、100、1000、10000nmol/L)を行った。1H-1,2,4-オキサジアゾール-(4,3a)-キノキサリン-1-オン(ODQ)含有時の評価の場合、10μmol/L ODQをPhe投与10分前に添加し、同様の評価を実施した。
EC50値はAssay Explorer(アクセルリス社)にて4パラメーターロジスティックモデルにより算出した。なお、試験化合物溶液は、各試験化合物を最終濃度の1000倍となるようにDMSOに溶解させた。
試験結果を表41に示す。
Claims (10)
- 一般式(1)
nは3から5の整数を示し;
X1及びX2は互いに独立してCH又はNを示し;
W1及びW2は互いに独立してカルボキシル基又はテトラゾリル基を示し;
VはC1-C8直鎖状又は分岐鎖状アルキレン基を示し、ここでメチレン基1個がO又はSで置換されていてもよく;
Rは下式
ここで、R1、R2、R3、R4及びR5は水素原子、ハロゲン原子、置換基を有しても良いC1-C6アルキル基、C1-C6アルコキシ基、C3-C6シクロアルキル基、C3-C6シクロアルコキシ基、ハロC1-C4アルキル基、ハロC1-C4アルコキシ基、置換基を有しても良いビニル基、置換基を有しても良いエチニル基、芳香環に置換基を有しても良いアリール基、芳香環に置換基を有しても良いアリールオキシ基、ベンゼン環に置換基を有しても良いベンジル基、ベンゼン環に置換基を有していても良いフェネチル基、ベンゼン環に置換基を有していても良いベンジルオキシ基、ベンゼン環に置換基を有していても良いベンジルスルファニル基、ベンゼン環に置換基を有していても良いベンジルアミノ基、ベンゼン環に置換基を有していても良いフェニルオキシメチル基、ベンゼン環に置換基を有していても良いフェニルスルファニルメチル基又はベンゼン環に置換基を有していても良いフェニルアミノメチル基を示し、
mは1又は2の整数を示し、
Y1及びY2は互いに独立してメチレン、O又はSを示し、ただし同時にSでない。)
で表される化合物、その薬学的に許容される塩又はそれらの溶媒和物。 - R1、R2、R3、R4及びR5におけるC1-C6アルキル基上の置換基が、C1-C6アルコキシ基、C3-C6シクロアルキル基又はC3-C6シクロアルコキシ基であり、ビニル基又はエチニル基上の置換基が、C1-C6アルキル基、、C3-C6シクロアルキル基、フェニル基、ハロゲノフェニル基、C1-C6アルキルフェニル基又はハロC1-C4アルキルフェニル基であり、アリール又はアリールオキシ上の置換基が、ハロゲン原子、C1-C6アルキル基、C1-C6アルコキシ基又はハロC1-C4アルキル基であり、ベンゼン環上の置換基が、ハロゲン原子、C1-C6アルキル基又はハロC1-C4アルキル基である請求項1記載の化合物、その薬学的に許容される塩又はそれらの溶媒和物。
- 次の化合物、その薬学的に許容される塩又はそれらの溶媒和物。
1-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}インダン-5-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-6,7,8,9-テトラヒドロ-5H-ベンゾシクロヘプテン-2-カルボン酸
4-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}クロマン-7-カルボン酸
4-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}チオクロマン-7-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロキノリン-2-カルボン酸
3-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-2,3-ジヒドロベンゾフラン-6-カルボン酸
4-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-フェニルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-イソクロマン-7-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(2-クロロベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-[2-[2-(4-ベンジルオキシベンジルオキシ)フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-[2-[2-(4-ベンジルスルファニルベンジルオキシ)フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-フェノキシメチルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-フェニルスルファニルメチルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-エチニルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-シクロヘキシルエチニルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-((E)-2-シクロヘキシルエテニル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[4-(2-シクロヘキシルエチル)ベンジルオキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[トランス-4-(2-フェニルエチル)シクロヘキシルメトキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-[シス-4-(2-フェニルエチル)シクロヘキシルメトキシ]フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(5,6,7,8-テトラヒドロナフタレン-1-イルメトキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-[2-[2-(3-tert-ブチルベンジルオキシ)フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-シクロプロピルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(4-イソプロピルベンジルオキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-[2-[2-[(1R)-1-(4-tert-ブチルフェニル)エトキシ]フェニル]エチル]-N-(4-カルボキシブチル)アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸
5-{N-(4-カルボキシブチル)-N-[2-[2-(インダン-2-イルメトキシ)フェニル]エチル]アミノ}-5,6,7,8-テトラヒドロナフタレン-2-カルボン酸 - 請求項1~5のいずれかに記載の化合物、その薬学的に許容される塩又はそれらの溶媒和物を含有する医薬。
- 請求項1~5のいずれかに記載の化合物、その薬学的に許容される塩又はそれらの溶媒和物、及び薬学的に許容される担体を含有する医薬組成物。
- 可溶性グアニル酸シクラーゼが関与する疾患を予防又は治療するための、請求項1~5のいずれかに記載の化合物、その薬学的に許容される塩又はそれらの溶媒和物。
- 可溶性グアニル酸シクラーゼが関与する疾患の予防又は治療薬を製造するための、請求項1~5のいずれかに記載の化合物、その薬学的に許容される塩又はそれらの溶媒和物の使用。
- 請求項1~5のいずれかに記載の化合物、その薬学的に許容される塩又はそれらの溶媒和物の有効量を投与することを特徴とする、可溶性グアニル酸シクラーゼが関与する疾患の予防又は治療方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/394,652 US9290440B2 (en) | 2012-04-16 | 2013-04-15 | Bicyclic compound |
CN201380020122.0A CN104245663B (zh) | 2012-04-16 | 2013-04-15 | 二环化合物 |
EP13778508.5A EP2840076B1 (en) | 2012-04-16 | 2013-04-15 | Bicyclic compound |
JP2014511214A JP6118965B2 (ja) | 2012-04-16 | 2013-04-15 | 2環性化合物 |
CA2870430A CA2870430A1 (en) | 2012-04-16 | 2013-04-15 | Polycyclic fused ring amino compounds |
RU2014145819A RU2640416C2 (ru) | 2012-04-16 | 2013-04-15 | Бициклическое соединение |
KR1020147028504A KR20140144696A (ko) | 2012-04-16 | 2013-04-15 | 2환성 화합물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-092783 | 2012-04-16 | ||
JP2012092783 | 2012-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013157528A1 true WO2013157528A1 (ja) | 2013-10-24 |
Family
ID=49383484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/061231 WO2013157528A1 (ja) | 2012-04-16 | 2013-04-15 | 2環性化合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9290440B2 (ja) |
EP (1) | EP2840076B1 (ja) |
JP (1) | JP6118965B2 (ja) |
KR (1) | KR20140144696A (ja) |
CN (1) | CN104245663B (ja) |
CA (1) | CA2870430A1 (ja) |
RU (1) | RU2640416C2 (ja) |
WO (1) | WO2013157528A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8981104B2 (en) | 2012-07-20 | 2015-03-17 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
US20150174113A1 (en) * | 2012-07-20 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
CN105777592A (zh) * | 2016-02-15 | 2016-07-20 | 高飞 | 一种药物中间体硝基取代磺酰类化合物的合成方法 |
WO2018016611A1 (ja) | 2016-07-22 | 2018-01-25 | トーアエイヨー株式会社 | 緑内障治療薬 |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2573644A (en) * | 1949-03-22 | 1951-10-30 | Smith Kline French Lab | beta-chloroethyl aminoindanes |
WO2001019780A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
JP2006523722A (ja) * | 2003-04-17 | 2006-10-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 過剰増殖性障害の処置に有用なヒドロキサム酸 |
WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
WO2009071504A1 (en) | 2007-12-03 | 2009-06-11 | Smithkline Beecham Corporation | 2,6-disubstituted pyridines as soluble guanylate cyclase activators |
WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
WO2010078900A2 (de) * | 2008-12-19 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue aliphatisch substituierte pyrazolopyridine und ihre verwendung |
WO2012165399A1 (ja) * | 2011-05-30 | 2012-12-06 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ544689A (en) * | 2001-11-06 | 2007-08-31 | Novartis Ag | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
GT200400070A (es) * | 2003-04-17 | 2004-11-30 | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos | |
TW201028152A (en) | 2009-01-20 | 2010-08-01 | Merck & Co Inc | Soluble guanylate cyclase activators |
DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
PT2875003T (pt) | 2012-07-20 | 2017-02-16 | Bayer Pharma AG | Novos ácidos 5-amino-tetra-hidroquinolina-2-carboxílicos e sua utilização |
US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
-
2013
- 2013-04-15 EP EP13778508.5A patent/EP2840076B1/en not_active Not-in-force
- 2013-04-15 CN CN201380020122.0A patent/CN104245663B/zh not_active Expired - Fee Related
- 2013-04-15 RU RU2014145819A patent/RU2640416C2/ru not_active IP Right Cessation
- 2013-04-15 KR KR1020147028504A patent/KR20140144696A/ko active IP Right Grant
- 2013-04-15 CA CA2870430A patent/CA2870430A1/en not_active Abandoned
- 2013-04-15 WO PCT/JP2013/061231 patent/WO2013157528A1/ja active Application Filing
- 2013-04-15 US US14/394,652 patent/US9290440B2/en not_active Expired - Fee Related
- 2013-04-15 JP JP2014511214A patent/JP6118965B2/ja active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2573644A (en) * | 1949-03-22 | 1951-10-30 | Smith Kline French Lab | beta-chloroethyl aminoindanes |
WO2001019780A2 (de) | 1999-09-13 | 2001-03-22 | Bayer Aktiengesellschaft | Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
JP2006523722A (ja) * | 2003-04-17 | 2006-10-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 過剰増殖性障害の処置に有用なヒドロキサム酸 |
WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
WO2009071504A1 (en) | 2007-12-03 | 2009-06-11 | Smithkline Beecham Corporation | 2,6-disubstituted pyridines as soluble guanylate cyclase activators |
WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
WO2010078900A2 (de) * | 2008-12-19 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue aliphatisch substituierte pyrazolopyridine und ihre verwendung |
WO2012165399A1 (ja) * | 2011-05-30 | 2012-12-06 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
Non-Patent Citations (8)
Title |
---|
"European Respiratory Journal", vol. 32, 2008, EUROPEAN RESPIRATORY SOCIETY, pages: 881 - 891 |
"Handbook of Experimental Pharmacology", vol. 191, 2009, SPRINGER-VERLAG, pages: 277 - 308 |
"Handbook of Experimental Pharmacology", vol. 191, 2009, SPRINGER-VERLAG, pages: 309 - 339 |
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN LTD., article "Development of Pharmaceutical Products", pages: 163 - 198 |
"The Journal of Clinical Investigation", vol. 113, 2004, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, pages: 352 - 354 |
"The Journal of Clinical Investigation", vol. 116, 2006, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, pages: 2552 - 2561 |
PROG. MED., vol. 5, 1985, pages 2157 - 2161 |
T. W. GREENE; P. G. WUTS: "Greene's Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS, INC. |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10053428B2 (en) | 2012-07-20 | 2018-08-21 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
US20150174113A1 (en) * | 2012-07-20 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
JP2015522597A (ja) * | 2012-07-20 | 2015-08-06 | バイエル ファーマ アクチエンゲゼルシャフト | 新規の5−アミノテトラヒドロキノリン−2−カルボン酸およびその使用 |
JP2015524401A (ja) * | 2012-07-20 | 2015-08-24 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用 |
US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
US9688636B2 (en) | 2012-07-20 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
US8981104B2 (en) | 2012-07-20 | 2015-03-17 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
CN105777592A (zh) * | 2016-02-15 | 2016-07-20 | 高飞 | 一种药物中间体硝基取代磺酰类化合物的合成方法 |
CN105777592B (zh) * | 2016-02-15 | 2017-11-07 | 吴丽清 | 一种药物中间体硝基取代磺酰类化合物的合成方法 |
WO2018016611A1 (ja) | 2016-07-22 | 2018-01-25 | トーアエイヨー株式会社 | 緑内障治療薬 |
US10682323B2 (en) | 2016-07-22 | 2020-06-16 | Toa Eiyo Ltd. | Therapeutic agent for glaucoma |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Also Published As
Publication number | Publication date |
---|---|
CN104245663A (zh) | 2014-12-24 |
EP2840076B1 (en) | 2017-10-25 |
CA2870430A1 (en) | 2013-10-24 |
JP6118965B2 (ja) | 2017-04-26 |
CN104245663B (zh) | 2016-10-26 |
KR20140144696A (ko) | 2014-12-19 |
US20150119418A1 (en) | 2015-04-30 |
EP2840076A1 (en) | 2015-02-25 |
RU2640416C2 (ru) | 2018-01-09 |
JPWO2013157528A1 (ja) | 2015-12-21 |
US9290440B2 (en) | 2016-03-22 |
RU2014145819A (ru) | 2016-06-10 |
EP2840076A4 (en) | 2015-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6118965B2 (ja) | 2環性化合物 | |
JP6586492B2 (ja) | 4−アミノメチル安息香酸誘導体 | |
RU2315036C2 (ru) | Антагонист casr | |
JP5551597B2 (ja) | シクロアルキルアミン誘導体 | |
US6080768A (en) | Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system | |
US5674909A (en) | Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system | |
JP3231775B2 (ja) | 心循環器系に作用する2−アミノ−1,2,3,4−テトラヒドロナフタレン誘導体、それらを製造する方法、及びそれらを含む医薬組成物 | |
ES2907746T3 (es) | Compuestos de amida y uso de los mismos | |
JP5306387B2 (ja) | イバブラジンおよび薬学的に許容され得る酸とのその付加塩の新規な合成法 | |
EP3330263A1 (en) | Antitumor compound targeting idh2 mutation and method of use thereof | |
CA2429267C (fr) | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant | |
WO2018082567A1 (zh) | 一种含有氮杂环螺旋结构的高效ido/tdo双抑制剂 | |
US6063964A (en) | 5-hydroxymethyl-2-aminotetralins as cardiovascular agents | |
EP1019376A1 (fr) | Derives de pyridone, leur preparation et leur utilisation comme intermediaires de synthese | |
JP2772650B2 (ja) | 新規化合物およびその医薬的用途 | |
US6232348B1 (en) | Hydroxymethyl derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene as cardiovascular agent | |
JPH0584301B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13778508 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014511214 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147028504 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013778508 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013778508 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2870430 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14394652 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014145819 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014025690 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014025690 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141015 |